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2. Abstract 
Background: Cystic fibrosis (CF) lung infection is a complex condition where 
opportunistic pathogens and defective immune system cooperate in developing a 
constant cycle of infection and inflammation. Despite the polymicrobial nature of 
this pathology, Pseudomonas aeruginosa is considered the major pathogen. 
Several mechanisms contribute to its successful colonization of CF airways; 
among these, virulence factors are important players. This thesis includes two 
studies aimed to evaluate aspects of P. aeruginosa interaction with both host and 
other microorganisms, like the emerging pathogen Achromobacter xylosoxidans. 
 
PROJECT 1 - Role of Pseudomonas aeruginosa virulence factors on lung 
inflammatory response: an in vivo imaging approach 
Methods: Pyocyanin, pyoverdine and proteases were measured in bacterial 
culture supernatant. Lung inflammatory response to bacterial exoproducts was 
monitored by in vivo imaging in wild-type and CFTR-knockout mice expressing 
luciferase gene under control of a bovine IL-8 promoter, and by evaluation of 
immune cells and cytokines in bronchoalveolar lavage. 
Results: P. aeruginosa grown in presence of sub-inhibitory doses of macrolides 
azithromycin and clarithromycin showed diminished levels of the secreted 
virulence factors. Intratracheal challenge with culture supernatant induced a 
strong inflammatory response in mouse lungs, while lack of virulence factors 
corresponded to reduction of inflammation. Particularly, inactivation of bacterial 
proteases by human matrix metalloprotease inhibitors Ilomastat and Marimastat 
also resulted in decreased lung inflammation, similarly to what previously 
observed with macrolides. 
Conclusions: Our data suggest that virulence factors are involved in P. 
aeruginosa pro-inflammatory activity. Particularly, proteases seem to play a 
critical role; thus, their inhibition potentially represents an additional therapeutic 
approach for P. aeruginosa-infected CF patients. 
 
PROJECT 2 - Adaptive microbial interactions between Pseudomonas aeruginosa 
and Achromobacter xylosoxidans  
Methods: P. aeruginosa and A. xylosoxidans clinical isolates were longitudinally 
collected from a chronically co-infected patient. Genotypic analysis was 
performed by pulsed-field gel electrophoresis. Phenotype was evaluated in terms 
of colony morphology, growth rate, adhesion ability, biofilm formation, and 
protease secretion.  
Results: The patient was colonized with the same clonetypes for 3 years. During 
this time, P. aeruginosa underwent phenotypic evolution while A. xylosoxidans 
showed no phenotypic changes. A. xylosoxidans could initially affect P. 
aeruginosa growth, adhesion and biofilm formation; later, this inhibitory effect 
disappeared and the two pathogens could form mixed biofilms. A. xylosoxidans 
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proteases down-regulation was observed over time, along with P. aeruginosa 
increased resistance to these exoproducts. 
Conclusions: During long term cohabitation in CF lungs, initial competitive 
interactions between A. xylosoxidans and P. aeruginosa seem to evolve towards 
reciprocal adaptation, which might represent a survival advantage. 
 
General conclusions: Understanding which mechanisms are primarily involved 
in P. aeruginosa successful colonization of CF lungs is essential to prevent the 
establishment of chronic infection and to find new therapeutic approaches. The 
studies here presented contribute to this knowledge, pointing at bacterial virulence 
and inter-species interactions as critical players. 
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3. Abbreviations 
AprA: alkaline protease 
ASL: airway surface liquid 
BALF: bronchoalveolar lavage fluid 
bIL-8-Luc: bovine IL-8 promoter/luciferase reporter 
CF: cystic fibrosis 
CFTR: cystic fibrosis transmembrane conductance regulator 
DPB: diffuse panbronchiolitis 
EMEM: Eagle’s minimum essential medium 
EPS: exopolysaccharide 
FEV1: Forced expiratory volume in the 1st second 
FVC: forced vital capacity 
GFP: green fluorescent protein 
KO: CFTR-knockout 
IL: interleukin 
LB: Luria Bertani medium 
LPS: lipopolysaccharide 
LasB: elastase B 
MIC: minimum inhibitory concentration 
MMP: matrix metalloprotease 
PFGE: pulsed-field gel electrophoresis 
QS: quorum sensing 
TSB: tryptic soy broth 
WBC: white blood cells 
WT: wild-type 
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4. Background 
4.1. Cystic fibrosis 
Epidemiology 
Cystic fibrosis (CF) is the most common life-threatening recessively inherited 
disease in the Caucasian population, counting approximately 80.000 diagnosed 
people in the world. Incidence shows wide geographic variations, ranging from 1 
in 1400 to 6000 live births in Europe (excluded Finland, where it is rare). Other 
areas of high diffusion are North America, Australia and New Zealand, Israel and 
Lebanon, while it is extremely rare in Asia, especially in China and Japan (Fig. 1). 
However, it is likely that CF is under-diagnosed in South America, Africa and 
Asia [1].  
 
Figure 1. CF prevalence and most common CFTR mutations by country. Birth 
prevalence is reported as number of live births per case of CF. Common/important 
mutations in each region are listed below the prevalence. The birth prevalence can vary 
greatly between ethnic groups in a country. (O'Sullivan BP, Freedman SD. Lancet 2009) 
 
Genetic defect 
The disease is caused by mutations in the CFTR (CF transmembrane conductance 
regulator) gene, situated in the long arm of chromosome 7 (7q31.2) [2, 3] and 
encoding the CFTR protein, which mainly functions as a chloride channel in 
exocrine epithelia. Up to date, over 2000 different CFTR mutations have been 
identified (www.genet.sickkids.on.ca), causing CFTR dysfunction through a 
variety of different mechanisms, categorized in 6 major classes (Fig. 2). Mutations 
belonging to classes 1 to 3 cause diminished or non-functional CFTR protein at 
the membrane and are associated with severe CF phenotypes, while class 4 and 5 
mutations are associated with residual CFTR-mediated chloride transport and 
milder phenotypes. Relatively novel class 6 mutations are characterized by high 
15 
 
 
CFTR turnover at the cell surface, promoting a functional but unstable mature 
CFTR protein [4, 5]. 
 
Figure 2. Classification of CFTR mutations. Class I: lack of CFTR synthesis; class II: 
defective protein processing; class III: defective channel regulation or gating; class IV: 
defective chloride conductance; class V: reduced amount of CFTR protein; class VI: 
increased turnover of CFTR channel at the cell surface. (Rowe SM, Miller S, Sorscher EJ. 
N Engl J Med 2005). 
 
CFTR functions 
The CFTR channel belongs to the superfamily of ABC (ATP binding cassette) 
transmembrane transporters. It is mainly located in the apical membrane of 
epithelial cells lining secretory organs, although it is also found in non-epithelial 
tissues like cardiac myocytes, smooth muscle, erythrocytes and immune cells [6-
11]. Structurally, CFTR is a 1480 amino acid membrane-bound glycoprotein 
comprised of two six-span transmembrane domains, MSD1 and MSD2, each 
connected to a cytoplasmatic nucleotide-binding domain (NBD) that hydrolyses 
ATP. These two units are connected through a regulatory domain, which is a 
unique feature of CFTR within the ABC superfamily [12, 13]. CFTR gating is 
thought to occur by protein kinase A phosphorylation of the R domain and 
recruitment of ATP on the NBDs, that induce conformational changes in the 
protein resulting in channel opening and closing upon ATP hydrolysis (Fig. 3) 
[14-16].  
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Figure 3. Structure of CFTR channel. CFTR is composed of five domains: two six-
span transmembrane domains (MSDs), two nucleotide-binding domains (NBDs), and a 
regulatory (R) domain. MSD-1 and MSD-2 are each bound to a NBD, forming two units 
connected through the R domain. The MSDs form the channel pore, phosphorylation of 
the R domain determines channel activity, and ATP hydrolysis by the NBDs controls 
channel gating. (Davidson DJ and Dorin JR. Expert Reviews in Molecular Medicine 
2001) 
 
CFTR has an additional role in the regulation of cell ionic transport, by repressing 
the epithelial sodium channel ENaC and controlling the renal outer medullary 
potassium channel ROMK2, the outwardly rectifying chloride channel ORCC, the 
calcium-activated chloride channel CaCC, the sodium/proton exchanger NHE3, 
and an aquaporin channel [17-21]. Moreover, CFTR is also involved in 
bicarbonate-chloride exchange, ATP transfer, intracellular vesicle transport, 
acidification of intracellular organelles, glutathione extracellular transport, and 
inflammation processes [22-27].  
Clinical manifestations 
CFTR absence or low-functioning leads to insufficient chloride secretion in the 
secretory epithelia, causing excessive reabsorption of ions and water and final 
dehydration and thickening of secretions. An exception are sweat glands, where 
CFTR channel function is reverse and its dysfunction produces sweat containing 
elevated chloride (>60mmol/L) and sodium concentrations [28]. The name “cystic 
fibrosis” refers to the characteristic fibrosis and cyst formation within the 
pancreas, due to the stasis of viscous pancreatic juices into pancreatic ducts. The 
resulting pancreatic insufficiency, observed in around 85% of patients, leads to 
steatorrhea, malabsorption syndrome, malnutrition, hypoproteinemia, and 
pancreatitis. Pancreatic abnormalities can also cause CF-related diabetes, which 
has a prevalence around 25% in patients aged >25 years. Thickened secretions 
also cause liver problems because of bile ducts obstruction, leading to cirrhosis 
and yellow jaundice. In addition, ionic imbalance in the biliary tract may lead to 
increased risk of gall stone and hepatobiliary disease [29]. Early gastrointestinal 
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manifestations include meconium ileus, occurring in 10-17% of patients within 
the first days of life [30]. Around 97-98% of male patients are infertile because of 
atrophic or absent vasa deferentia, while fertility problems due to thickened 
cervical mucus affect 25% of CF females [31, 32]. While CF is a multiorgan 
disease, pulmonary involvement is the major cause of morbidity and ultimate 
mortality. Thickened mucus obstructs distal airways, promoting bronchiectasis 
and bacterial infections, followed by intense neutrophil recruitment. Chronic 
infections and progressive inflammation favor tissue degradation, leading to final 
lung failure [33]. 
 
4.2. Lung pathophysiology 
Pathogenesis 
CFTR is expressed in the submucosal glands and the apical surface of ciliated 
epithelial cells [34, 35]. In normal airways, mucus is constantly cleared by the 
mucociliary system thanks to airway surface liquid (ASL) volume autoregulation. 
Although pathogenesis of CF lung disease is not completely clear yet, studies 
have suggested that defective chloride and bicarbonate transport, coupled with 
altered regulation of sodium transport, lead to excessive reabsorption of sodium 
and water from the airway surface liquid, causing dehydration of the mucus layer 
and depletion of the periciliary layer, with consequent inability of the cilia to 
remove the thickened mucus [36]. Mucus stasis promotes airways blockage and 
bronchiectasis, and impairs clearance of inhaled microorganisms. Relatively 
minor early infections may induce an exaggerated and prolonged inﬂammatory 
response. Infection persistence leads to chronic inflammation and finally to 
progressive loss of lung function (Fig. 4) [37, 38].  
 
Figura 4. The CF pathogenesis cascade in the lung. The mechanism of CF dysfunction 
starts with the primary CFTR gene defect, which alters the airway surface volume (ASL) 
and leads to bronchiectasis, lung damage by a cycle of inflammation and infection, and 
ultimate severe lung deficiency. (Amaral MD. Journal of Internal Medicine 2015). 
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Inflammation 
Normal airways are protected from infection by host defense system, and airway 
macrophages complement epithelial defenses. In the CF airways, inﬂammation 
begins early in life and may occur independently of infection. Chronic 
inflammation, mainly characterized by neutrophils recruitment, is the result of 
increased activation of the inﬂammatory response combined with inability to 
terminate and resolve inﬂammation. Inhibition of CFTR production or function in 
epithelial cell lines was associated with increased activation of the pro-
inﬂammatory transcription factor NFkB, and reduced production of IFN-γ that 
leads to stimulation of neutrophil chemokines [39-44]. The CF airway contains 
large concentrations of several pro-inﬂammatory mediators including TNF-α, IL-
1β, IL-6, IL-8, IL-17, IL-33, GM-CSF, G-CSF, and HMGB-1, mainly involved in 
neutrophil stimulation, clearance regulation, oxidative and secretory responses 
[44-47]. Particularly, IL-8 and IL-17 are strong promoters of neutrophils 
recruitment [48, 49]. CF airways are also deﬁcient in several counter-regulatory 
molecules including IL-10, nitric oxide, and lipoxin-A4, mainly involved in 
inflammatory response downregulation and termination [45, 50-55]. Thus, an 
imbalance in anti-inflammatory molecules may be as important as the numerous 
pro-inﬂammatory pathways for the persistence of host inﬂammatory response, 
helping to explain observations of inﬂammation in the absence of infection. 
Neutrophils normally secrete antimicrobial peptides, eliminate microorganisms 
through opsonophagocytosis, trap bacteria in extracellular traps consisting of 
extruded DNA, and digest bacteria intracellularly by autophagy. Recent studies 
demonstrated that neutrophil phagolysosomes express CFTR, whose absence or 
defect cause abnormal chlorination of engulfed pathogens and impaired microbial 
killing [11, 56, 57]. In CF, these potentially malfunctioning neutrophils 
accumulate in the airways by a combination of excessive influx and decreased 
clearance. Massive amounts of neutrophil chemoattractants are present in CF 
airways [58]. Particularly, IL-8 concentration in bronchoalveolar lavage fluid 
(BALF) has been shown to often correlate with the concentration of neutrophils 
and their products [48]. Neutrophils are usually removed by cough clearance or 
alveolar macrophages phagocytosis, but in CF cough clearance is reduced and the 
ability of macrophages to scavenge apoptotic neutrophils (efferocytosis) also 
appears abnormal [59]. Rather than clearance by normal apoptotic mechanisms, 
CF neutrophils often undergo necrosis [60]. Decomposing neutrophils release 
large amounts of intracellular contents: chemoattractants fuel further neutrophils 
influx, DNA increases the viscosity of endobronchial secretions, oxidants induce 
oxidative stress and promote IL-8 production, and proteases mainly damage 
airways structure [61, 62]. Particularly, neutrophil elastase can disrupt lung tissue, 
contribute to mucociliary impairment, support neutrophils influx, hinder 
phagocytosis and efferocytosis, and degrade CFTR [63-69]. Detection of 
neutrophil elastase in BALF has been shown to predict early bronchiectasis in CF 
children, and its concentration in sputum correlates with FEV1 decline [70-72]. 
Recently also macrophages demonstrated to play a critical role in CF 
inflammation process. Macrophages normally phagocyte microbes, microbial 
products and cellular debris, and produce pro-inflammatory cytokines in response 
to pathogen exposure. In CF, macrophages are present in high concentrations in 
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the BALF of young patients, but appear to be dysregulated: differentiation in cell 
subtypes is altered, exposure to bacterial lipopolysaccharide induces an excessive 
production of pro-inflammatory mediators, bacterial killing and efferocytosis 
abilities are impaired [10, 59, 73-76].  
Infection 
Ineffective mucociliary clearance and defective innate immune defenses allow 
bacterial infections to establish in CF airways. Early acquisition of pathogenic 
bacteria and development of chronic infections are associated with increased 
morbidity and mortality. Colonization with Pseudomonas aeruginosa, the most 
common pathogen isolated from CF airways, is particularly difficult to eradicate 
and is associated with acceleration of decline in lung function and with poorer 
prognosis [77]. Other respiratory pathogens play a role at different stages of the 
lung disease: Staphylococcus aureus and Haemophilus influenzae are the main 
pediatric pathogens, while Burkholderia cepacia complex (Bcc), Achromobacter 
xylosoxidans, Stenotrophomonas maltophilia and nontuberculous mycobacteria 
are mainly found in adults (Fig. 5) [78]. Particularly, A. xylosoxidans recently 
gained attention as an important emerging pathogen that can cause severe chronic 
infection associated with lung inflammation and decline of respiratory function 
[79-81], further complicated by its innate and acquired multidrug resistance 
hindering eradication therapies [82, 83]. Bcc is a group of phenotypically similar 
species of the genus Burkholderia that have been associated with worse outcomes 
and survival in CF patients, and heightened mortality following lung 
transplantation [84]. Also, anaerobe bacteria seem to have a role in exacerbations 
[85, 86]. In addition to bacterial infections, many patients present infections with 
Aspergillus sp. and some exhibit the syndrome of allergic bronchopulmonary 
aspergillosis [87].  
 
Figure 5. Prevalence of respiratory CF pathogens by age of patients. S. aureus and H. 
influenzae are the main pediatric pathogens, while P. aeruginosa, B. cepacia complex, 
Achromobacter spp., and S. maltophilia are mainly found in adults. Multidrug resistant S. 
aureus and P. aeruginosa are reported as MRSA and MDR-PA, respectively. (US CFF 
Patient Registry, Annual Data Report 2014). 
 
Apart from classical pathogens, a large number of microorganisms described as 
the “CF microbiome” has been identified [88], and CF lung infection has been 
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highlighted as a polymicrobial condition, highly heterogeneous between patients 
and fluctuating over time [89]. It is likely that pathogens and commensals could 
engage intra- and inter-species interactions, acting competitively or synergistically 
with each other to gain an adaptive advantage through the production of 
antimicrobial chemicals to compete and signal molecules to cooperate, thereby 
influencing community composition, resistance to antibiotics, and course of 
airway disease [90, 91]. Interactions are favored by microbial proximity, 
promoted by intra- and inter-species co-aggregation in biofilm communities [92, 
93]. Biofilm mode of growth, typical of chronic infections, allows bacteria to 
form highly organized, structured aggregates attached on the epithelial surface, 
using self-produced extracellular polymeric substance (EPS) containing nucleic 
acids, polysaccharides, and other macromolecular components like proteins, 
lipids, biosurfactants, flagella and pili. The EPS matrix imparts both a physical 
and chemical robustness to the community by resisting mechanical forces and 
decreasing the penetration of toxic chemicals like antibiotics and host defense 
molecules [94, 95]. Thus, biofilms decrease bacterial susceptibility to 
antimicrobial agents, promoting bacterial tolerance and/or resistance, and favoring 
the failure of eradication therapies [96].  
 
4.3. Pseudomonas aeruginosa  
CF airways infection 
P. aeruginosa is a Gram-negative rod that can act as an opportunistic pathogen 
causing chronic respiratory infections in more than 50% of CF patients, with 
higher prevalence in adults [97-99]. A period of intermittent, recurrent lung 
colonization with P. aeruginosa is described, when antibiotic treatment can 
temporarily eradicate the infection and recolonization with another genotype 
occurs [100]. However, a recolonization with the same genotype occurs in 
approximately 25% of the patients, probably by bacterial aspiration from the 
sinuses in which the bacteria might adapt before infecting the lung [101, 102]. 
This intermittent colonization phase, which can last for years, sooner or later 
transitions into a chronic infection (Fig. 6). In the lower respiratory tract, the 
biofilm mode of growth of P. aeruginosa induces a state of chronic inflammation, 
which is unable to clear the infection and causes instead pulmonary damage [103]. 
The gradual decrease in lung function is most likely the result of accumulation of 
focal infections over time [104]. Increased number of neutrophils, alveolar 
macrophages and T lymphocytes were found in alveoli of explanted lungs from 
infected CF patients [105]. Despite the inflammatory response and intensive 
antibiotic therapy, most infections caused by P. aeruginosa persist for long time, 
eventually leading to respiratory failure and lung transplantation or death [106]. 
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Figure 6. Schematic representation of the typical progression of P. aeruginosa 
infection. Different colors represent phylogenetically independent P. aeruginosa clones. 
Intermittent colonization can be eradicated, and the patients can be negative for 
P. aeruginosa for up to several years. The process is repeated until a chronic infection is 
established. (Folkesson A et al, Nature Reviews 2012) 
 
Genotypic and phenotypic diversification of P. aeruginosa occurs both in the 
lungs and in the paranasal sinuses, with emergence of alginate hyperproducing, 
mucoid isolates (Fig. 7) [101, 107, 108]. The most common mutations responsible 
for the mucoid conversion are found in mucA, which encodes an inner-membrane-
associated anti-σ-factor [109, 110]. MucA normally limits the expression of the 
algD operon, which encodes the enzymes required for alginate synthesis, by 
sequestering the alternative RNA polymerase σ-factor σ22, encoded by algU (also 
known as algT) [111-115]. Additionally, σ22 regulates a large number of stress 
response and virulence-associated genes and is involved in the regulation of 
virulence and motility (Fig. 8) [115-118]. The mucoid phenotype has been 
associated with biofilm mode of growth, increased endobronchial inflammation, 
increased antibody response and poorer lung function [119, 120].  
 
 
 
Figure 7. Typical morphology of non-mucoid (left) and mucoid (right) P. aeruginosa 
clinical isolates. Mucoid phenotype is due to alginate overproduction. (Verzè S., 
unpublished). 
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Figure 8. Regulation network of MucA–σ22. The function of the RNA polymerase σ-
factor σ22 is antagonized through protein–protein binding by the anti-σ-factor MucA. 
Mucoid P. aeruginosa isolates often carry knockout mutations in mucA, leaving σ22 free 
to activate transcription of many genes, such as those involved in alginate production and 
the responses to heat shock, osmotic stress and oxidative stress. σ22 also negatively 
regulates several virulence factors, including flagella, pili, the type III secretion system 
(T3SS), Rhl quorum sensing signals, as well as Rhl-controlled rhamnolipids. (Folkesson 
A et al, Nature Reviews 2012). 
 
Infections by P. aeruginosa are difﬁcult to treat because of its intrinsic ability to 
resist many classes of antibiotics as well as its ability to acquire resistance. 
Intrinsic resistance is due to the low permeability of its outer membrane, the 
constitutive expression of membrane efﬂux (Mex) pumps, and the natural 
occurrence of an inducible chromosomal β-lactamase, AmpC. Acquired resistance 
can result from genetic transfer of resistance genes, or mutations in antibiotic 
targets or genes regulating intrinsic resistance mechanisms. Adaptive resistance 
occurs when environmental stressing conditions cause a change in gene 
expression, resulting in upregulation of genes that can confer resistance [121, 
122]. Development of resistance to antipseudomonal drugs is often seen in the 
non-mucoid isolates and has been associated with occurrence of hypermutability 
[123]. Acquisition of multidrug-resistant (MDR) P. aeruginosa was not found to 
be associated with decline of lung function in CF patients [124]; thus, MDR P. 
aeruginosa is rather a marker of advanced disease than the cause of it.  
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Interactions with other bacteria 
Given the polymicrobial nature of CF lung infection, P. aeruginosa is often co-
isolated with other microbial species sharing the same environment, both 
pathogens and commensals. In the case of chronic co-infections, this cohabitation 
can last for long time; thus, it is likely that P. aeruginosa and its neighbors 
residing in the same niche can engage interactions, potentially influencing the 
course of infection and therapies [90, 91]. 
P. aeruginosa interactions with classical main pathogens Burkholderia spp. and S. 
aureus have extensively been studied. Cooperation between P. aeruginosa and B. 
cenocepacia was reported: alginate production by P. aeruginosa mucoid 
phenotype contributes to B. cenocepacia persistence, co-infection of P. 
aeruginosa and B. cenocepacia in mice results in greater levels of bioﬁlm 
formation and enhanced inﬂammatory response, polymyxin B-susceptible P. 
aeruginosa appears to beneﬁt from the more resistant B. cenocepacia within the 
same population [125-127]. However, the two species also show competitive 
interactions: P. aeruginosa can inhibit Burkholderia spp. by S-type pyocin, a 
toxin with antibacterial activity [128]. Interestingly, the bactericidal activity of 
pyocin is greater in anaerobic conditions, and it is also active against cells in the 
bioﬁlm mode of growth [129, 130]. Interactions between P. aeruginosa and S. 
aureus provide a potential explanation for the limited isolation of S. aureus in 
late-stage CF lung disease: P. aeruginosa mucA mutants compromise S. aureus 
growth, and P. aeruginosa elastase A and tetramic acids exhibit anti-
staphylococcal activity [131, 132]. Furthermore, P. aeruginosa quinolone signals 
select for the highly antibiotic resistant S. aureus small colony variants, which are 
able to persist viable inside host cells [133]. This latter ﬁnding is supported by 
clinical data indicating that CF patients with methicillin-resistant S. aureus have 
poorer outcomes when associated with P. aeruginosa infection [134]. 
As regards interactions with emerging pathogens like S. maltophilia and A. 
xylosoxidans, the available information has lesser extent, mainly due to the recent 
identification of these microorganisms as important CF pathogens. Recently, S. 
maltophilia has been reported to have modulatory activity on P. aeruginosa 
virulence in mixed biofilm; further investigations will reveal the outcome of this 
interaction, which might confer selective ﬁtness advantage to P. aeruginosa or, 
alternatively, increase its virulence leading to pulmonary exacerbation [135]. Up 
to date, studies about P. aeruginosa possible interactions with A. xylosoxidans 
lack, despite the frequent co-isolation of the two microorganisms from sputum 
samples and the increasing number of patients becoming chronically infected with 
A. xylosoxidans [81, 136, 137].   
Virulence factors 
Especially during early infection, P. aeruginosa expresses a wealth of virulence 
factors exhibiting strong pro-inflammatory properties (Fig. 9) [138]. 
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Figure 9. A multitude of virulence factors are produced by P. aeruginosa. Flagella 
and type 4 pili are the main adhesins, T3SS can inject cytotoxins directly into the host 
cell, and a wealth of secreted factors have various effects on host. (Gellantly SL and 
Hancock REW. Pathogens and Disease 2013). 
 
Flagella and type 4 pili are the main means of motility and adhesion to host 
epithelial cells. Each P. aeruginosa cell possesses a single polar ﬂagellum and 
several type 4 pili, also localized at a cell pole. The flagellum, responsible of 
swimming motility, can bind to host epithelial ganglioside asialoGM1 and can 
elicit a strong NFkB-mediated inﬂammatory response [139]. Many isolates from 
chronic infections demonstrate downregulation of ﬂagella and ﬂagella-mediated 
motility [140]. Type 4 pili are responsible of twitching motility and, together with 
ﬂagella, facilitate swarming motility, a coordinated form of motility on semi-solid 
surfaces [141, 142]. Moreover, they contribute to formation of biofilms, 
promoting bacteria aggregation on target tissues [143, 144]. Pili are also involved 
in bacterial phagocytosis by macrophages, and pili-deficient mutants 
demonstrated reduced virulence [145].  
Lipopolysaccharide (LPS) is a component of the outer membrane and has roles in 
antigenicity, inﬂammatory response, exclusion of external molecules, and in 
mediating interactions with antibiotics [146]. P. aeruginosa produces a three-
domain LPS consisting of a membrane-bound lipid A, a core region, and a highly 
variable O-antigen. While penta-acylated lipid A form is predominant in 
laboratory strains, isolates from chronically infected CF lungs show hexa- and 
sometimes hepta-acylated species with increased inﬂammatory properties, and the 
extent of these modiﬁcations appears to increase with the severity of lung disease 
[147]. “O-speciﬁc” polysaccharide is an O-antigen variable which elicits a strong 
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antibody response [146]. Interestingly, many chronic P. aeruginosa isolates lose 
the expression of this variable over time [148].  
Type 3 secretion system (T3SS) can inject toxins directly into host cells. As such, 
its expression is frequently associated with acute invasive infections and has been 
linked to increased mortality in infected patients [149, 150], while T3SS mutants 
displayed attenuated virulence [151]. Nearly all strains express one of the two 
major exotoxins exoU or exoS (rarely both) and minor exotoxins exoY and exoT 
[150, 152]. Recently, it was reported that nucleoside diphosphate kinase is also 
translocated into host cells by T3SS [153]. The exact contribution of each effector 
to pathogenesis is unclear, but it is thought that the T3SS may allow P. 
aeruginosa to exploit breaches in the epithelial barrier by antagonizing wound 
healing during colonization, and to promote cell injury [150].  
Quorum sensing (QS) small membrane-diffusible molecules, called autoinducers, 
are the mediators of bacterial coordinated adaptation to the lung environment. 
These molecules are constitutively produced by each bacterium and act as 
cofactors of speciﬁc transcriptional regulators when they reach high enough 
threshold concentrations. When the bacterial population increases to a critical 
mass (i.e. “quorum”), the concentration of autoinducers becomes sufﬁcient to 
cause activation of specific downstream genes, resulting in a coordinated response 
across the entire bacterial population. It is estimated that 10% of genes and more 
than 20% of the expressed bacterial proteome are regulated by QS [154]. P. 
aeruginosa produces three autoinducers: two acyl homoserine lactones (AHLs) 
and the Pseudomonas quinolone signal (PQS), regulated by Las and Rhl systems 
[154, 155]. Cell survival, bioﬁlm formation, and virulence are controlled by these 
systems; thus, strains deﬁcient in any of these systems show reduced 
pathogenicity [149, 156, 157]. 
P. aeruginosa secretes several proteases, which can degrade host complement 
factors, mucins, surfactant and disrupt tight junctions between epithelial leading to 
dissemination of the bacteria [156, 158, 159]. Alkaline protease (AprA) is a type 
1-secreted zinc metalloprotease known for its degradation of host complement 
proteins and ﬁbronectin [160]. It can also modulate inflammatory and immune 
responses by reduction of the bioavailability of several cytokines and inhibition of 
RANTES [161-164]. In a murine model of sepsis, AprA in combination with 
exotoxin A administered as an inactivated toxoid vaccine demonstrated signiﬁcant 
protection against subsequent infection by P. aeruginosa [165]. Moreover, AprA 
has been shown to degrade free ﬂagellin monomers, thereby helping P. 
aeruginosa to avoid immune detection [166]. Furthermore, AprA has been 
reported to proteolytically activate ENaC channel, contributing to alter fluid 
secretion and pathogens clearance in CF airways [167]. P. aeruginosa also 
produces two elastases, LasA and LasB, which are regulated by QS and secreted 
via type 2 secretion system [168, 169]. LasB is a metalloprotease that can degrade 
lung surfactant proteins A and D [170] and cause ruptures in the respiratory 
epithelium through tight-junction destruction, increasing epithelial permeability 
and facilitating neutrophil recruitment [171]. It can also decrease host immune 
response through alteration of key membrane receptors such as proteinase-
activated receptor 2 and urokinase-type plasminogen activator receptor, and 
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inactivation of inflammatory cytokines such as TNF-α and IFN-γ [164, 172, 173]. 
Interestingly, lasB mutants are less virulent and more susceptible to phagocytosis 
[174]. LasA is a serine protease, thought to enhance the proteolytic activity of 
LasB [169, 175]. Another serine protease is protease IV, which can degrade 
complement proteins, immunoglobulins, and ﬁbrinogen. Protease IV degradation 
of host surfactant proteins A and D inhibits the association of P. aeruginosa with 
alveolar macrophages, helping P. aeruginosa survival during infection [176]. 
The blue-green pigment pyocyanin causes host cells oxidative stress by disrupting 
mitochondrial electron transport and cellular protective mechanisms of host 
enzymes catalase, superoxide dismutase and glutathione peroxidase [177-179]. 
Puriﬁed pyocyanin can induce apoptosis in neutrophils as well as inhibit the 
phagocytosis of apoptotic bodies by macrophages [180-182]. It is also able to 
modulate IL-2, IL-8 and RANTES expression by airway epithelial cells and 
suppress cilia beating [183-187]. Moreover, pyocyanin is thought to play a 
protective role against the reactive oxygen and nitrogen species produced by 
phagocytic cells, to induce increased levels of neutrophil elastase, and to 
contribute to biofilm formation by promoting extracellular DNA release [188-
191].  
The siderophore pyoverdine is both able to sequester iron from host depots and to 
act as a signaling molecule. Iron chelation is a vital part of establishing infections, 
as the host environment has little free iron due to its own sequestration molecules. 
Iron-bound pyoverdine starts a cell-surface signaling cascade which directs the 
transcription of several genes involved in the regulation of exotoxin A, 
endoprotease, and pyoverdine itself [192, 193]. The dual function of pyoverdine 
in iron uptake and virulence renders this siderophore essential for P. 
aeruginosa infectivity, as demonstrated in different mouse models [194, 195]. 
Pyoverdine production was found to be influenced by several environmental 
signals and regulatory pathways, including oxygen and nutrient availability, 
oxidative stress, cellular aggregation [196, 197]. 
Exotoxin A inhibits host cell elongation factor 2 (EF2), thereby inhibiting protein 
synthesis and leading to cell death. It is also involved in repression of the host 
immune response and can induce apoptosis [198-200]. In the presence of iron 
ions, exotoxin A expression is upregulated by pyoverdine [193]. 
Lipase and phospholipase can target lipids in the lung surfactant and 
phospholipids in host cell membranes [156]. Surfactants degradation by 
phospholipase causes an increase in surface tension [201].  
 
4.4. Achromobacter xylosoxidans 
Infection 
Achromobacter species are ubiquitous Gram-negative bacilli, widely distributed 
in aquatic environments and soil, increasingly found in nosocomial setting. They 
are opportunistic pathogens in certain populations, such as subjects with CF, 
where these microorganisms can survive for long time in both lower and upper 
airways [308]. Among CF patients, the most often isolated species is A. 
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xylosoxidans, whose chronic lung colonization has been associated with decline in 
respiratory function and lung inflammation [81, 308, 309]. Infection results either 
from acquisition from the environment or from direct/indirect transmission [310, 
311], and is usually complicated by the innate and acquired multidrug resistance 
carried by these microorganisms. Approximately 50 drug-resistance associated 
genes have been predicted in A. xylosoxidans type strain, and a rich variety of 
mobile genetic elements carrying resistance genes have been identified in clinical 
isolates [312, 313]. All together, these features characterize A. xylosoxidans as an 
important emerging CF pathogen. 
Virulence factors 
Similar to other gram-negative pathogens, Achromobacter spp. express cell 
membrane-bound virulence factors, like the Vi capsular polysaccharide, involved 
in surface adhesion and protection from phagocytosis and toxins, and the O-
antigen, which elicits host immune response [314]. LPS as well induces key 
inflammatory cytokines [315]. A. xylosoxidans is also equipped with various 
secretion systems that mediate the release of molecules to provide capability for 
invasion of the host cells [316, 317], but few is known about its exoproducts. 
Genome analysis showed the presence of genes encoding colicin V, a protein 
cytotoxic to similar bacteria, and AepA, involved in cellulase and protease 
regulation [316]. In addition, production of phospholipase C and ability to 
inactivate P. aeruginosa quinolone signal molecule were observed [318, 319]. 
Moreover, a heat-stable cytotoxic factor, associated with increase of pro-
inflammatory cytokines in vitro, was identified [320]. Jakobsen and collegues also 
investigated the presence of secreted virulence factors known to be important for 
other CF pathogens like P. aeruginosa, but reported the absence of extracellular 
proteases, chitinase and rhamnolipids [316].  
As regards the biofilm mode-of-growth, Achromobacter spp. is highly motile 
(swimming) via long, peritrichous flagella but lacks twiching motility, which is 
considered necessary for the development of surface-attached biofilm, as it 
probably contributes to stabilize interactions with the surface [321]. Indeed, poor 
adhesion ability in vitro was reported [316]. Reduction of surface attachment over 
time of infection was also shown in sequential CF clinical isolates, in association 
with acquisition of mutations in genes with a presumptive role in surface adhesion 
[317, 322]. However, a recent study from Nielsen and collegues highlighted 
Achromobacter spp. ability to form unattached or loosely attached aggregates, 
held together by polysaccharides forming a peripheral shell around the bacterial 
cells [322]. 
 
4.5. Anti-inflammatory therapy in cystic fibrosis 
Macrolides 
Macrolide antibiotics are 14-, 15-, and 16-member lactone monocycles, known to 
have antibacterial properties (Fig. 10). They bind to the 23S rRNA in the 50S 
subunit of the bacterial ribosome, thereby inhibiting protein synthesis and 
bacterial growth [202]. In addition, 14- and 15-members have also 
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immunomodulatory effects. They act through different mechanisms at the level of 
the immune system, ultimately interfering with immune activation and cytokines 
production (Fig. 10) [203, 204]. 
 
Figure 10. Immunomodulatory and antibacterial activity of macrolides. On the host 
side, macrolides induce macrophages activation, downregulate lymphocytes, and reduce 
the release of pro-inflammatory cytokines from neutrophils and epithelial cells. On the 
bacterial side, they favor phagocytosis and downregulate protein synthesis and biofilm 
formation mainly by interfering with quorum sensing system. (Wong EH et al. Lancet 
Respiratory Medicine 2014). 
 
Azithromycin is a 15-member macrolide widely used as low-dose continuous 
treatment in P. aeruginosa chronically infected patients. Although it has no 
bactericidal activity against P. aeruginosa, several clinical investigations have 
revealed that azithromycin treatment improves respiratory function and reduces 
the occurrence of pulmonary exacerbations and the frequency of courses of 
antibiotic therapies [205-208]. It has also been demonstrated that the amounts of 
neutrophils and some plasma inflammatory markers are significantly reduced by 
azithromycin treatment; these changes are associated with the improvement of 
respiratory function [209, 210]. Although the mechanisms are still not clear, it is 
thought that azithromycin beneficial effects are due to a combination of anti-
pseudomonal and immunosuppressive activity [211]. Sub-inhibitory azithromycin 
concentrations can downregulate protein synthesis in P. aeruginosa and suppress 
motility and production of several virulence factors, including proteases, 
pyocyanin, exotoxin A, phospholipase C, and EPS [212-219]. Azithromycin also 
interferes with QS system, down-regulating the expression of many QS-dependent 
genes, as those encoding pili, ﬂagellum, and oxidative stress response proteins 
[220-222]. Moreover, azithromycin can increase P. aeruginosa susceptibility to 
serum bactericidal activity, probably by altering lipopolysaccharides and outer 
membrane proteins, and to some antimicrobials, and promote killing of stationary-
phase and bioﬁlm-forming cells [223-227]. Azithromycin has also anti-
inflammatory effects independent from its anti-virulence activity, since it can 
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reduce various serum inflammatory markers and increase pulmonary function in 
non-infected patients, although with less extent than in chronically infected 
patients [209, 210, 228]. Beneﬁcial effects have so far been documented in CF 
patients treated with azithromycin for up to 6 months, while reduced efﬁcacy was 
associated with longer treatment duration, probably due to development of 
bacterial resistance to its anti-virulence activity [228, 229]. 
Clarithromycin is a 14-member macrolide known to modulate pro-inflammatory 
cytokine expression, probably due to downregulation of NF-κB and other pro-
inflammatory pathways [48, 230, 231]. Clarithromycin treatment was evaluated in 
several chronic respiratory diseases characterized by airways inflammation. Low-
dose clarithromycin demonstrated clinical effectiveness in treating diffuse 
panbronchiolitis (DPB), which shares many similarities in clinical and 
pathological characteristics with CF and is often treated with erythromycin, 
another 14-membered macrolide [232-234]. In patients with bronchiectasis, 
clarithromycin treatment decreased inflammatory cytokines and leukocytes 
number in BALF, exhaled breath condensate and peripheral blood [231, 235].  
Moreover, short term clarithromycin administration demonstrated to reduce 
chronic airways hypersecretion [236]. Different studies evaluating clarithromycin 
therapy in CF patients were conducted, reporting contrasting results. In a study in 
which patients were treated with 250 mg clarithromycin on alternate days for a 
year, the treatment resulted in a marked reduction of cytokine levels in both 
sputum and plasma as well as a significant improvement in both FEV1 and FVC 
[237]. In contrast, in two studies examining daily administration of 500 mg 
clarithromycin, there was no significant difference in the pulmonary function, in 
neutrophils number and inflammatory cytokines in the sputum after the treatment 
[238, 239]. In an additional study using 15 mg/kg/day clarithromycin for 3 
months, the treatment led to a decrease in acute pulmonary exacerbations and 
improvement in clinical status, but it did not cause a significant fall in 
inflammatory cytokines in the BALF of CF patients [240]. Although low-dose 
clarithromycin might be more effective as supported by its low-dose (200 mg/day) 
benefits in treatment of DPB [232], the comparison of the outcomes of these 
studies is limited by the different treatment regimens, drug doses and 
formulations, and clinical factors evaluated; thus, further trials are necessary to 
assess the effects of clarithromycin treatment in CF patients. As regards P. 
aeruginosa infection, clarithromycin has no bactericidal activity against the 
microorganism, like other macrolides. Nonetheless, it showed to have inhibitory 
activity against P. aeruginosa protease expression, twitching motility and biofilm 
maturation, promoting biofilm permeability and favoring penetration of other 
antimicrobial agents like ciprofloxacin and tobramycin [217, 241-248]. 
Clarithromycin formulation as dry powder inhaler (DPI) for aerosol 
administration is currently under investigation [249, 250]. At present, the only 
antibiotic available as DPI is tobramycin; therefore, clarithromycin-tobramycin 
local co-administration in the airways represents an interesting therapy for the 
treatment of chronic P. aeruginosa pulmonary infection [251].   
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Protease inhibitors 
Excessive and dysregulated secretion of host and bacterial proteases in the CF 
lung strongly contribute to exacerbation of the inflammatory response and lung 
damage (Fig. 11). Although the main source of protease activity is thought to be 
activated neutrophils, it became evident that exogenous P. aeruginosa proteases 
disrupt key host processes by several means such as activation of cascade 
pathways, disruption of cytokine signaling, inactivation of cell receptors and host 
protease inhibitors [252]. Therefore, protease-inhibiting molecules could target 
the damaging effects of bacterial secreted proteases limiting host inflammatory 
response and lung damage. 
 
Figure 11. Proteases in CF airways. The overwhelming of the airway innate anti-
protease shield by excessive and dysregulated secretion of host and bacterial proteases in 
the CF lung leads to exacerbation of the inflammatory response and lung damage. (Quinn 
DJ et al, The Open Respiratory Medicine Journal 2010). 
The most potent protease inhibitors are hydroxamate-based broad spectrum matrix 
metalloprotease (MMP) inhibitors, which mimic collagen structure, thus binding 
to the enzyme active site and inactivating it by chelation of the catalytic zinc ion. 
Interestingly, their inhibitory effect can apply also to bacterial metalloproteases, 
as it has been demonstrated by Ilomastat (Galardin, GM6001) ability to inhibit 
thermolysin and P. aeruginosa elastase [79, 253-257]. Ilomastat is under 
evaluation as treatment for sulfur mustard inhalation injury and chemical burns, 
ocular implantation, dental caries, and as inhaled treatment for chronic obstructive 
pulmonary disease [258-262]. Several MMP inhibitors also entered clinical trials 
as anticancer agents during the 90’s, but their clinical performance was 
disappointing [263, 264]. The first MMP inhibitor to be clinically tested was 
Batimastat, an injectable drug. Although effective for malignant ascites and 
malignant pleural effusion, due to its poor solubility and very low oral 
bioavailability trials were stopped during phase III in favor of the newer, orally 
available analogue Marimastat [265, 266]. During clinical trials Marimastat 
showed a favorable pharmacokinetic profile, high systemic bioavailability, linear 
dose-plasma relationship, balanced excretion (75% hepatic, 25% renal), an 
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elimination half-life compatible with twice-daily dosing, and modest efficacy in 
delaying disease progression; however, significance could not be established due 
to dose-limiting toxicity, identified with appearance of musculoskeletal symptoms 
reversible upon drug discontinuation [264, 267-269]. 
Targeting of bacterial proteases involved in chronic infection processes such as 
dysregulation of the inflammatory response would be a useful addition to CF 
therapeutic treatments. Furthermore, unlike traditional antibiotics which target 
fundamental processes thereby creating enormous selection pressures, anti-
protease therapy should be less likely to result in the generation of resistant 
pathogens [252].  
 
4.6. Mouse models for studying CF lung inflammation 
CF models 
CF animal models are powerful tools that enable the study of the mechanisms and 
complexities of human disease. Murine models have several intrinsic advantages 
compared with other animal models, including lower cost, maintenance, and rapid 
reproduction rate. Up to date, eleven CF transgenic or knockout mouse models 
have been characterized (Tab. 1) [270]. With an overall aminoacid sequence 
homology of 78% between murine and human CFTR, these models have 
facilitated significant strides in our understanding of this complex disease. The 
first loss-of-function null murine model (CFTRtm1UNC) was generated by 
insertion of a stop codon in exon 10 of the CFTR coding sequence, termed S489X 
mutation, in embryonic stem cells [271]. Following this model, many others 
knockout models were developed on various genetic backgrounds 
(CFTRtm1CAM, CFTRtm1HSC, CFTRtm3BAY, CFTRtm3UTH, 
CFTRtm1HGU, CFTRtm1BAY) [272-275, 286]. To overcome the limitations 
imposed by the severe intestinal disease presented by many knockout strains, 
“gut-corrected” hybrid strains were created using a transgene expressing CFTR 
from a promoter specific for the intestinal epithelium [307]. In addition to the CF 
knockout models, various knock-in mutants were also developed. Specific CF-
causing mutations were introduced in the endogenous mouse CFTR gene to bear 
mice carrying the class II ΔF508 (CFTRtm1EUR, CFTRtm1KTH, 
CFTRtm2CAM) and G480C (CFTRtm3HGU) mutations, the class III G551D 
(CFTRtm2HGU) mutation, and the class IV R117H (CFTRtm2UTH) mutation 
[276-280, 286]. However, intra-mutant variations in the survival, disease severity, 
and pathology of these animals have been reported. Although not a typical CFTR 
murine model, the 𝛽-ENaC mouse model has also been considered. The channel, 
in concert with CFTR-mediated chloride secretion, plays an important role in the 
proper regulation of ASL volume and in the adequate clearance of inhaled 
microorganisms and environmental particulates by the mucociliary system [281].  
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Table 1. CF mouse models 
Identifier Mutation 
References 
CFTRtm1UNC Exon 10 replacement 
[271] 
CFTRtm1CAM Exon 10 replacement 
[272] 
CFTRtm1HSC Exon 1 replacement 
[275] 
CFTRtm3BAY Exon 2 replacement 
[274] 
CFTRtm3UTH Exon 4 replacement 
[286] 
CFTRtm1HGU Exon 10 insertion  
[286] 
CFTRtm1BAY Exon 3 insertion 
[273] 
CFTRtm2CAM ΔF508, exon 10 replacement 
[278] 
CFTRtm1KTH ΔF508, exon 10 replacement 
[277] 
CFTRtm1EUR ΔF508, exon 10 insertion (hit and run) 
[276] 
CFTRtm2HGU G551D, exon 11 replacement 
[280] 
CFTRtm3HGU G480C, exon 10 insertion (hit and run) 
[279] 
CFTRtm2UTH R117H, exon 4 replacement 
[286] 
Tg(FABPCFTR) 
Transgene expressing CFTR in intestinal villus 
epithelia 
[307] 
Tg(CCSPScnn1b) 
Transgene expressing Scnn1b in airway surface 
epithelia 
[281] 
 
Lung disease in CF models 
While the upper respiratory tract of the murine models is representative of the 
upper airways of humans with CF, the lower airways represent an entirely 
different picture. No CFTR mouse model develops spontaneous lung 
inflammation without challenge, limiting their usefulness in the study of 
pulmonary disease progression in CF [271-273, 275-277, 279, 280, 282]. The lack 
of severe spontaneous lung pathology in these mouse models has been partially 
attributed to the expression of a non-CFTR calcium-activated chloride channel 
(CaCC) in certain mouse tissues: its expression might rectify the ion imbalance 
underlying CF lung disease. Only a congenic strain of the CFTRtm1UNC mouse 
model, termed B6-CFTRtm1UNC, in which the murine-expressed alternative 
chloride channel is absent, was reported to develop spontaneous lung disease 
including impaired mucociliary clearance and tissue fibrosis even when bred in a 
pathogen-free environment. These congenic mice also displayed impaired control 
of P. aeruginosa infection [283, 284]. The development of chronic pulmonary 
inflammation and bacterial persistence has been reported in the CFTRtm1UNC 
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model following intranasal challenge with B. cepacia, with increased neutrophil 
counts and cytokine levels [285]. Significant pulmonary inflammation and 
associated pathology were also induced in CFTRtm1UNC mice following 
intratracheal delivery of P. aeruginosa-embodied agarose beads [286]. 
Furthermore, low ATP12A proton-pump expression levels in CF mice may allow 
for normal ASL pH and unimpaired airway host defenses. Such findings may 
explain why CF mice exhibit increased protection from pulmonary infection 
[287].  
Lung inflammation: methods and models 
In vivo studying lung inflammation is essential for the development of new 
therapies and for the characterization of the pathological processes. Frequently in 
mouse models, inflammation is induced by invasive lung challenge with bacterial 
cells or bacterial products with pro-inflammatory activity such as LPS. 
Inflammation is then monitored by recovery of BALF from the killed animals and 
by analyzing the presence of inflammatory markers such as immune cells and 
cytokines. Thus, the conventional assessments of inflammation in mice often rely 
on invasive ex vivo measurements which cause the death of the animal and are 
consequently particularly onerous when expensive transgenic mice are utilized. 
Moreover, when applied to CF transgenic mice this protocol may not be fully 
reproducible, probably due to the heterogeneity of airway inflammation in CF. 
Furthermore, although this approach is extensively used and highly validated, it 
precludes the possibility to repeat longitudinally the assessment of test animals 
[288-290]. However, in vitro and in vivo new protocols in animal models have 
been used to study the mechanism of lung inflammation in chronic diseases and to 
evaluate the anti-inflammatory role of some candidate molecules [291, 292]. 
Recently emerging non-invasive imaging technologies such as magnetic 
resonance imaging (MRI), micro-CT and optical imaging have been applied to 
longitudinal monitoring of airway remodeling and inflammation in murine models 
[293-296]. The clinical imaging system used in MRI, CT and PET, have been 
further adapted to murine models of asthma [293, 297-299], to serve as a 
preclinical and translational step between basic discovery and clinical practice, 
whereas optical imaging technologies developed in experimental settings may 
also slow-down their way into the clinical practice, especially in the context of 
intra-operative activities [300, 301]. Recently, a mouse model transiently 
expressing the luciferase reporter gene under the control of a bovine IL-8 
promoter has been generated. Although mice do not express IL-8 or a clear 
homologous, the cell signaling and transcriptional apparatus could specifically 
activate the exogenous IL-8 promoter [302].  
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5. Objectives 
The main objective of this study was to evaluate some aspects of P. aeruginosa 
interaction with both CF host and other co-infecting microorganisms, like the 
emerging pathogen A. xylosoxidans. 
To this purpose, the thesis is divided in two projects: 
• Regarding P. aeruginosa interaction with host, we studied in vivo lung 
inflammation induced by P. aeruginosa exoproducts, and evaluated the anti-
inflammatory effects of molecules inhibiting the synthesis/activity of P. 
aeruginosa secreted virulence factors, to better understand their role in CF 
lung inflammatory disease. For this study, an innovative in vivo imaging 
approach was developed and applied to CF animals. 
• About P. aeruginosa interactions with co-infecting microorganisms, we 
observed inter-species interactions between P. aeruginosa and A. xylosoxidans 
longitudinal isolates chronically co-infecting the same patient, in order to 
investigate the possible competitive/synergistic effects of their long-term 
cohabitation and the role of bacterial interactions on their survival and 
persistence in the human host. 
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6. PROJECT 1 - ROLE OF P. AERUGINOSA VIRULENCE FACTORS ON LUNG 
INFLAMMATORY RESPONSE: AN IN VIVO IMAGING APPROACH 
In the present study, using non-invasive imaging techniques we monitored mouse 
lung inflammation induced by virulence factors released by P. aeruginosa and 
evaluated the anti-inflammatory action of molecules inhibiting the 
synthesis/activity of bacterial factors involved in pathogenicity. The mouse model 
here used allowed to detect in vivo the activation of an exogenous bovine IL-8 
promoter via a luciferase reporter, responsible of bioluminescence emission. 
Although mice do not bear a clear IL-8 homologous, activation of the exogenous 
promoter could be detected in different mouse strains. 
 
6.1. Materials & Methods 
Bacterial strains 
Two P. aeruginosa clinical isolates were selected, VR1 and VR2. The strains 
were isolated from sputum samples from two intermittently infected patients 
followed at the Cystic Fibrosis Center of Verona. Strains were stored in 
MicrobankTM (Pro-Lab Diagnostics, Neston, UK) at -80°C. 
Minimum inhibitory concentration assay 
P. aeruginosa strains were streaked on Blood Columbia agar plates (Oxoid, 
Milan, Italy) and incubated at 37°C for 24-48 hours. 1-2 colonies were inoculated 
in 10 ml LB (Luria-Bertani) broth shaking at 37°C for 16 hours. OD600 was 
measured, cultures were diluted to 0.1 OD/ml and inoculated in 96-wells 
microtiter plates with increasing concentrations of azithromycin and 
clarithromycin. Plates were incubated at 37°C for 16 hours and OD600 was 
measured. The minimum inhibitory concentration value corresponds to the lower 
dose of antibiotic causing a complete inhibition of the culture turbidity. 
Bacterial growth and culture supernatant collection 
P. aeruginosa strains were streaked on LB or TSA (tryptic soy agar) plates and 
incubated at 37°C for 24-48 hours. 1-2 colonies were inoculated in 30 ml LB, KB 
(King’s broth) or TSB (tryptic soy broth) shaking at 37°C for 16 hours. OD600 was 
measured and cultures were diluted to 0.1 OD/ml in 30 ml of the same medium, 
with/without sub-MIC azithromycin (8 µg/ml) or clarithromycin (45 µg/ml). After 
shaking at 37°C for 16 hours, cultures were diluted to 0.2 OD/ml and centrifuged 
at 7000 g for 30 min at 4°C. Supernatants were collected and sterile-filtered. 
Virulence factors measurement: 
o Pyocyanin 
Pyocyanin was chloroform-extracted from LB supernatants. Briefly, 3 ml 
chloroform were added to 5 ml supernatant, and the lower phase was mixed with 
1 ml 0.2 M hydrogen chloride. OD530 was measured in the upper phase and 
pyocyanin concentration was calculated by multiplying for its ɛ-1 (17,072 µg/ml 
cm) and normalizing for the optical distance. 
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o Pyoverdine 
OD405 of KB culture supernatants was measured and pyoverdine concentration 
was calculated using its ɛ (19 mM-1 cm-1) and normalizing for the optical distance. 
 
o Proteases 
Protease activity in TSB culture supernatants was determined by azocasein assay. 
Briefly, 350 µl reaction mixture containing 0.1 M Tris-HCl, pH 8.0, and 1% 
azocasein (Sigma-Aldrich, previously resuspended in 0.5% NaHCO3) was added 
to 150 µl supernatant, with/without protease inhibitors (Ilomastat, Marimastat, 
Batimastat), and incubated at 37°C for 20 minutes shaking. After addition of 1 ml 
7% ice-cold perchloric acid, the solution was centrifuged. 150 µl 10 N sodium 
hydroxide were added to the clear supernatant and OD430 was measured. One 
protease unit was calculated as the amount of enzyme producing an increase of 
0.1 OD per hour. 
o Metalloproteases 
Metalloprotease activity in TSB culture supernatants was assayed by gelatin 
zymography. 20 µl of supernatant in non-reducing sample buffer (0.125 Mm Tris 
base pH 6.8, 1.25% SDS, 5% glycerol, trace bromophenol blue) were loaded in a 
polyacrylamide gel containing 0.1% gelatin. The gel was run at 200 V, 14 mA for 
1-1.5 hours, washed twice in 2.5% Tryton X-100 for 20 minutes shaking and 
incubated in renaturing buffer (10 Mm Tris-HCl pH 7.5, 1.25% Triton X-100, 5 
mM calcium chloride, 1 µM zinc chloride) at 37°C for 16 hours shaking. After 
Coomassie Blue staining and water destaining, areas of degradation appeared as 
clear bands against a dark background.  
o Alkaline protease 
Alkaline protease in TSB culture supernatants was quantified by western blot 
using a specific anti-AprA antibody (kind gift of Prof. Gerd Döring, University of 
Tubingen, Germany). 20 µl of TCA-precipitated supernatant in reducing sample 
buffer (0.05 mM Tris base pH 6.8, 1 % SDS, 5% glycerol, 5% β-mercaptoethanol, 
trace bromophenol blue) were run in a polyacrylamide gel at 200 V, 14 mA for 
1.5 hours. Proteins were then transferred on a PVDF membrane at 100 V, 120 mA 
for 1 hour. The membrane was blocked for 1 hour shaking in 5% BSA, then 
incubated overnight with the anti-AprA primary antibody at 4°C shaking. After 1 
hour incubation with anti-rabbit secondary antibody, chemiluminescent images 
were acquired using ECL Western Blotting Substrate (Promega, Milan, Italy). 
Total proteins were quantified by electrophoresis in a polyacrylamide gel in 
reducing conditions and Coomassie Blue staining. 
Supernatant concentration 
TSB supernatants were concentrated using 30 kDa cut-off Amicon Ultra-15 
centrifugal filter units (Merck Millipore, Tullagreen, Cork, Ireland) pre-coated 
with 10 mg/ml bovine serum albumin. Concentrate was centrifuged at 27.000 rpm 
to remove cell debris, supernatant was sterile-filtered and stored at -20°C. 
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Reporter construct 
Eukaryotic cells and experimental animals were transfected with the bIL-8-Luc 
construct, containing the luciferase gene under the control of bovine IL-8 
promoter (kind gift of Prof. Gaetano Donofrio, University of Parma, Italy). 
Plasmid was transformed in competent E. coli DH5α cells by heat shock and 
purified by Qiagen Plasmid Maxi Kit (Qiagen) followed by phenol:chloroform 
extraction with precipitation in isopropanol and 70% ethanol. Plasmid identity 
was verified by KnpI digestion and agarose gel electrophoresis. Concentration and 
purity were measured using NanoDrop 2000c spectrophotometer. 
Eukaryotic cells 
Mouse lung adenoma LA-4 cells were cultured in Dulbecco’s modified essential 
medium (DMEM, Lonza) with 2 mM L-glutamine and 10% fetal bovine serum, 
and detached with 0.25% trypsin-EDTA. Cell culture plates or flasks were 
incubated at 37°C with 5% CO2 in humidified atmosphere. 
Cell transfection 
LA-4 cells were plated in 24-wells plates (30.000 cells/well) and grown overnight. 
80% confluent cells were transfected with bIL-8-Luc construct alone or co-
transfected with bIL-8-Luc and pEGFP-C3 constructs (9:1 ratio) using 
Lipofectamine 2000 (Thermo Fisher Scientific). Briefly, 500 ng/well DNA and 
1.5 µl/well Lipofectamine were separately diluted in DMEM medium, mixed, 
incubated at room temperature for 5 minutes and added to the cells (50 µl/well). 
Reporter assays 
BIL-8-Luc transfected LA-4 cells were treated with 50 µl culture supernatant and 
luminescence was recorded using Luciferase Assay System (Promega). Briefly, 
cells were lysed with 100 µl 1X cell culture lysis reagent for 5 minutes, 
centrifuged at 12.000 g for 2 minutes at 4°C and supernatant was collected. In 96-
wells plates, 100 µl/well luciferase assay reagent (LAR) were added to 20 µl/well 
lysis supernatant and the light produced was measured using Victor2 microplate 
reader (Perkin Elmer). Prior to LAR addition, EGFP fluorescence in lysate 
supernatant was recorded (excitation 485 nm, emission 535 nm) as cells vitality 
control. Alternatively, 150 µg/ml D-Luciferin (Perkin Elmer) was added to the 
alive cells directly in the 24-wells plates and, after 10 minutes, bioluminescence 
was recorded using IVIS Lumina (Caliper Life Sciences). 
Experimental animals 
Female BalbC (7-8 weeks old) mice were purchased from Harlan Laboratories 
Italy (San Pietro al Natisone, Udine, Italy). Female congenic C57BL/6J WT and 
gut-corrected CFTRtm1UNC (8-10 weeks old) mice were purchased from Cystic 
Fibrosis animal Core facility (San Raffaele Hospital, Milan, Italy). Animals were 
maintained under conventional housing conditions. Prior to use, animals were 
acclimatized for at least 5-7 days to the local vivarium conditions, having free 
access to standard rodent chow and tap water.  
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In vivo gene delivery 
In vivo JetPEI (Polyplus Transfection) was used as carrier for delivering bIL-8-
Luc construct to lung tissue. DNA and JetPEI were mixed with a final N/P ratio of 
7-7.5 following manufacturer’s instructions. Briefly, 38-42 µg DNA and 5.3-6.3 
µl JetPEI were separately diluted in 200 µl 5% glucose, mixed, and incubated at 
room temperature for 15 minutes. 400 µl/mouse of the mixture were intravenously 
injected through the tail vein after warming the animals for 5 minutes under a 
heating lamp. Expression and inactivation of the reporter were monitored by in 
vivo imaging after 24 hours and 7 days, respectively. 
Intratracheal challenge 
Starting 7-10 days and until 30 days after in vivo gene delivery, bIL-8-Luc 
transiently transgenic mice were intratracheally challenged with TSB culture 
supernatant. Briefly, mice were anesthetized with 2.5% isoflurane and placed on 
an intubation platform hanging by their incisor teeth. After visualization of the 
opening of the trachea using a laryngoscope, 50 µl supernatant were instilled by 
an intubation tube connected to a pressure control system. After 4, 24 and 48 
hours, reporter activation was monitored by in vivo imaging.  
In vivo bioluminescence imaging 
Bioluminescence imaging of experimental animals was performed using IVIS 
Lumina imaging system (Caliper Life Sciences, Alameda, CA). 10 minutes prior 
to bioluminescence recording, mice were anesthetized with 2.5% isoflurane and 
intraperitoneally injected with 150 mg/kg D-Luciferin (Perkin Elmer). After 5 
minutes-long luminescence recording, photons emitted from chest region were 
quantified using Living Image software (Caliper Life Sciences, Alameda, CA). 
Bronchoalveolar lavage fluid analysis  
Trachea was cannulated with an 18-gauge catheter. 5 ml sterile phosphate buffer 
saline were instilled in the bronchial tree and collected. After red blood cells lysis 
(in 0.2% sodium chloride for 20 seconds followed by addition of 1.2% sodium 
chloride) and centrifugation at 400 g for 10 minutes, supernatant was frozen at 
−80 °C for quantification of multiple cytokines/chemokines using a Bio-Plex™ 
Cytokine Assay Kit (Bio-Rad Laboratories, Segrate, Milan, Italy), and the cell 
pellet was resuspended in PBS. After cells count, 50.000 cells were 
cytocentrifuged and stained with May-Grunwald and Giemsa for differential 
count. The number of cells per animal was calculated as the number of cells per 
ml of BALF multiplied for the volume used for the resuspension of the cells 
pellet. 
Statistical analysis 
Statistical analysis was performed using GraphPad Prism software. Virulence 
factors concentration and LA-4 cells bioluminescence emission were analyzed by 
t-test or 1way ANOVA, and mice bioluminescence, cell counts and cytokines 
were analyzed by 1way or 2way ANOVA. 
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6.2. Results 
P. aeruginosa virulence factors induce bovine IL-8 promoter activation 
To set up a convenient, non-invasive method for in vivo imaging of lung 
inflammation, we evaluated the expression of a construct containing a luciferase 
reporter gene under control of bovine IL-8 promoter (bIL-8-Luc). Culture 
supernatant containing P. aeruginosa exoproducts, collected from the virulent CF 
clinical isolate VR1, was used to verify the activation of the exogenous IL-8 
promoter both in vitro and in vivo. LA-4 murine lung adenoma cells were 
transfected with bIL-8-Luc construct, and treated with different concentrations of 
VR1 culture supernatant. The treatment induced a concentration-dependent 
bioluminescence emission, significantly higher in comparison to the control 
(tryptic soy broth culture medium, TSB) when using 10X-concentrated 
supernatant (Fig. 12A). As a vitality marker, cells were co-transfected with a 
construct containing enhanced Green Fluorescent Protein (GFP) gene under the 
control of a constitutive promoter. After challenge with culture supernatant, 
fluorescence emission was similar in treated and non-treated cells, confirming the 
same cellular vitality among the different treatment conditions (Fig. 12B).  
 
Figure 12. Light (A) and fluorescence (B) emission from bIL-8-Luc:eGFP co-transfected 
LA-4 cells treated with 3X and 10X concentrated VR1 culture supernatant. TSB was used 
as control. Each value represents the mean ± SD of 3 experiments. Statistical analysis was 
performed by 1way ANOVA followed by Dunnett’s multiple comparisons test, ** p<0.01 
vs. control. 
 
In bIL-8-Luc-transgenic BalbC mice, intratracheal instillation with different 
concentrations of VR1 culture supernatant induced bioluminescence emission in 
the lungs area (Fig. 13A). The photon emission was concentration-dependent and 
the maximal increase was reached with the 10X-concentrated supernatant (Fig. 
13B). Indeed, 30X-concentrated supernatant did not induce a further increase, 
indicating a saturation of the system with the 10X concentration, which was 
selected to be used for the following experiments. 
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Figure 13. Representative images of bIL-8-Luc-mediated bioluminescence emission in 
BalbC mice 24 hs after instillation with increasing concentrations of VR1 culture 
supernatant (A). TSB was used as control. Photons emission expressed as folds of 
increase (FOI) over baseline (B). Each value represents the mean ± SEM of 3 animals. 
Statistical analysis was performed by 1way ANOVA followed by Dunnett’s multiple 
comparisons test, * p<0.05 and ** p<0.01 vs. control. 
 
Inhibition of P. aeruginosa virulence factors by azithromycin decreases mice 
lung inflammation 
VR1 strain was grown in presence of 8 µg/ml azithromycin, a sub-inhibitory dose 
consistent with the range reported in the lungs of CF patients undergoing 
azithromycin therapy [305]. Growth of bacteria in presence of the macrolide 
reduced pyocyanin, pyoverdine and proteases levels in VR1 culture supernatant 
(Fig. 14A), confirming the known inhibitory effect of azithromycin on the 
synthesis of virulence factors. Particularly, inhibition of metalloprotease activity 
and alkaline protease (AprA) expression was detected in both culture supernatant 
and bacterial lysate (Fig. 14B), supporting that azithromycin interferes with 
metalloproteases synthesis. On the contrary, another P. aeruginosa CF clinical 
isolate, named VR2, was characterized by low levels of secreted virulence factors 
(Fig. 14A), and no metalloprotease activity/expression was detectable in its 
supernatant nor in the lysate (Fig. 14B). No significant difference in pyocyanin, 
pyoverdine and proteases levels was detected between supernatants from VR2 
grown in absence or presence of 8 µg/ml azithromycin (VR2+AZM). 
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Figure 14. Pyocyanin, pyoverdine and proteases concentration in culture supernatants 
from VR1 and VR2 isolates grown in presence/absence of azithromycin (AZM) (A). Each 
value represents the mean ± SEM of 3 experiments. Statistical analysis was performed by 
2-tailed t test, * p<0.05 and ** p<0.01. In both bacterial lysates and culture supernatants, 
metalloprotease activity and AprA expression were measured by zymography and 
western blot, respectively (B). Total proteins were quantified by electrophoretic 
separation on polyacrylamide gel. 
 
In LA-4 cells transfected with bIL-8-Luc construct, treatment with culture 
supernatant collected after VR1 growth in presence of azithromycin (VR1+AZM) 
induced a significantly lower bioluminescence emission in comparison to 
supernatant from non-treated VR1 (Fig. 15). This preliminary in vitro result 
suggests that the anti-virulence activity of azithromycin might be involved in its 
anti-inflammatory effect. 
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Figure 15. Light emission from bIL-8-Luc transfected LA-4 cells treated with 10X 
concentrated culture supernatant from VR1 isolate grown in presence/absence of 8 µg/ml 
azithromycin (AZM). TSB was used as control. Luminescence emission was recorded by 
IVIS Lumina system after addition of luciferin. Each value represents the mean ± SD of 3 
experiments. Statistical analysis was performed by 1way ANOVA followed by Dunnett’s 
multiple comparisons test, ** p<0.01 and *** p<0.001. 
 
In bIL-8-Luc-transgenic BalbC mice challenged with 10X-concentrated VR1 
supernatant, a strong bioluminescence emission was detectable already 4 hours 
after instillation and reached the highest peak after 24 hours. On the contrary, 
supernatant from VR1+AZM induced a low bioluminescence emission, 
comparable to that induced by VR2 supernatant, containing low levels of 
virulence factors (Fig. 16). No significant difference in bioluminescence emission 
was detected between mice treated with VR2 and VR2+AZM supernatants. 
 
Figure 16. Representative images of bIL-8-Luc-mediated bioluminescence emission in 
BalbC mice 4, 24 and 48 hs after instillation with 10X concentrated culture supernatants 
from VR1 and VR2 isolates grown in presence or absence of sub-MIC azithromycin 
(AZM). TSB was used as control (A). Photons emission is expressed as folds of increase 
(FOI) over baseline. Each value represents the mean ± SEM of 8 animals. Statistical 
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analysis was performed by 1way ANOVA followed by Dunnett’s multiple comparisons 
test, * p<0.05 and ** p<0.01 vs. control, # p<0.05 vs. treatment (B). 
 
Immune cells recruitment (Fig. 17A) and cytokines expression (Fig. 17B) were 
evaluated in BALF at 24 hours after challenge. VR1 supernatant significantly 
stimulated total white blood cells (WBC) and neutrophils recruitment, and the 
expression of IL-1β, TNF-α, IL-17, RANTES, KC, IL-12 (p70) and IL-12 (p40) 
cytokines. Inflammatory cells and expression of many cytokines were lower in 
mice treated with VR1+AZM supernatant, except for TNF-α and IL-12 (p40), or 
VR2 supernatant, except for RANTES and IL-12 (p40). No significant difference 
between the stimulation caused by VR2 and VR2+AZM supernatants was 
observed, except for RANTES and IL-12 (p40) levels. 
 
Figure 17. Immune cells recruitment (A) and cytokines expression (B) in BalbC mice 24 
hs after instillation with 10X concentrated culture supernatants from VR1 and VR2 
isolates grown in presence or absence of sub-MIC azithromycin (Az). TSB was used as 
control. The amount of white blood cells and neutrophils found in BALF was expressed 
as number of cells per μl. Cytokines concentration was expressed as folds of increase 
(FOI) over control. The experiment was repeated 3 times and each point represents the 
mean ± standard deviation of 8 animals. Results are reported as mean ± SEM. Statistical 
analysis was performed by 1way ANOVA followed by Dunnett’s multiple comparisons 
test, * p<0.05 and ** p<0.01 vs control, ## p<0.01 vs. treatment. 
P. aeruginosa protease inhibition decreases mice lung inflammation 
Since P. aeruginosa proteases contribute to inflammatory exacerbation, their 
inhibition might result in the reduction of lung inflammatory response. 
Hydroxamate-based broad spectrum human metalloprotease inhibitor Ilomastat 
was previously reported to inhibit P. aeruginosa elastase. To confirm this finding, 
we tested its inhibitory activity against VR1 secreted proteases, and observed that 
Ilomastat could inactivate P. aeruginosa proteases in 1X and even 10X-
concentrated culture supernatant (Fig. 18).  
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Figure 18. Protease activity in 1X (A) and 10X-concentrated (B) VR1 culture supernatant 
was measured in presence of increasing concentrations of Ilomastat (Galardin). Each 
value represents the mean ± SEM of 3 experiments. Statistical analysis was performed by 
Kruskal-Wallis test and Dunn’s multiple comparisons test for non-parametric data, * 
p<0.05 and *** p<0.001 vs non-treated supernatant. 
 
To verify whether inhibition of P. aeruginosa metalloproteases can influence and 
possibly reduce lung inflammation, bIL-8-Luc-transgenic BalbC mice were 
intratracheally challenged with VR1 supernatant pre-treated with Ilomastat: a 
reduced bioluminescence emission in comparison to non-pretreated supernatant 
was recorded at 24 hours after the challenge. The lower bIL-8 activation was 
similar to that previously observed with VR1+AZM challenge (Fig. 19A). 
Imaging data were supported by immune cells count in bronchoalveolar lavage 
fluid: total white blood cells and neutrophils recruitment was reduced when VR1 
supernatant was pre-treated with Ilomastat (Fig. 19B). 
 
 
Figure 19. bIL-8-Luc-mediated bioluminescence emission in BalbC mice 4 and 24 hs 
after instillation with 10X concentrated VR1 culture supernatant non-treated or pre-
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treated with 50 µM Ilomastat (Galardin), or from VR1 grown in presence or absence of 8 
µg/ml azithromycin (AZI). Photons emission is expressed as folds of increase (FOI) over 
baseline (A). Total white blood cells and neutrophils recruitment in BalbC mice 24 hs 
after instillation with 10X concentrated VR1 culture supernatant non-treated or pre-
treated with 50 uM galardin. The amount of immune cells found in BALF was expressed 
as number of cells per μl (B). TSB was used as control. Each point represents the mean ± 
SEM of 4 animals. Statistical analysis was performed by 1way ANOVA followed by 
Dunnett’s multiple comparisons test, * p<0.05 and ** p<0.01 vs. VR1. 
Adaptation of bIL-8-Luc model in CFTR-knockout mice 
In order to carry on anti-inflammatory molecules testing by in vivo imaging in a 
CF background, bIL-8-Luc model was adapted to C57BL/6J Cftrtm1Unc (KO) mice. 
Exogenous IL-8 promoter activation by P. aeruginosa exoproducts was verified 
after challenge with known P. aeruginosa pro-inflammatory stimuli, such as LPS 
and VR1 culture supernatant. After determining the optimal transfection 
conditions for this mouse strain, bIL-8-Luc congenic CFTR-KO and wild-type 
(WT) mice were intratracheally challenged with P. aeruginosa LPS 
(6.25 µg/mouse). LPS was previously resuspended in EMEM (Eagle's Minimum 
Essential Medium), which was used as control treatment. Both KO and WT mice 
responded to LPS reaching the maximum bioluminescence signal between 4 and 
24 hours after the challenge (Fig. 20). Moreover, lungs were excised and their 
imaging was performed: as clearly shown in ex vivo pictures, the bioluminescence 
signal was well localized in the lung (Fig. 20). Immune cells recruitment and 
cytokines expression were evaluated in BALF at 24 hours after the intratracheal 
challenge. White blood cells (WBC) and neutrophils recruitment increased in both 
mouse strains when treated with LPS, and eight pro-inflammatory cytokines (IL-
1β, IL-5, KC, IL-6, G-CSF, IFN-γ, MIP-1α, TNF-α) resulted up-regulated (Fig. 
21). 
 
Figure 20. Representative in vivo images of bIL-8-Luc-trasgenic WT and CFTR-KO 
(CF) mice intratracheally treated with P. aeruginosa LPS (6.25 µg/mouse) (A). EMEM 
was used as control (a, d). Bioluminescence images were recorded at 4 and 24 hours after 
intratracheal instillation with LPS (b, e). Lungs were excised and imaged 24 hs after LPS 
challenge (c, f). Time-course of IL-8-luc activation (B). Results are reported as folds of 
increase (FOI) over baseline. Each value represents the mean ± SEM of 6 animals. 
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Statistical analysis was performed by 1way ANOVA followed by Dunnett’s multiple 
comparisons test, * p<0.05 vs. control. 
 
Figure 21. Immune cells recruitment (A) and cytokines expression (B) in WT and CFTR-
KO (CF) mice 24 hours after instillation with P. aeruginosa LPS. EMEM was used as 
control. The amount of immune cells found in BALF was expressed as number of cells 
per μl (A). Cytokines concentration was expressed as pg/ml (B). Three mice were used 
for every time point and the experiment was replicated three times. Values are expressed 
as mean ± SEM of the three different experiments. Statistical analysis was performed by 
1way ANOVA followed by Dunnett’s multiple comparisons test, * p<0.05 and ** p<0.01 
vs control. 
 
In another set of experiments, WT and KO mice were challenged with 10X-
concentrated VR1 culture supernatant, which activated the exogenous IL-8 
promoter. Both mouse strains responded to the stimulus reaching the maximum 
BLI signal between 4 and 24 hours after the challenge (Fig. 22). Increase in total 
WBC and neutrophils in BALF was observed at 24 hours after VR1 culture 
supernatant treatment, as well as up-regulation of pro-inflammatory cytokines 
(Fig. 23). Thus, two different pro-inflammatory stimuli derived from P. 
aeruginosa had a similar behavior on bIL-8 activation in both WT and KO mice. 
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Figure 22. Representative in vivo images of bIL-8-Luc-trasgenic WT and CFTR-KO 
(CF) mice intratracheally treated with P. aeruginosa VR1 10X-concentrated culture 
supernatant (A). TSB was used as control (a, d). Bioluminescence images were recorded 
at 4 and 24 hours after intratracheal instillation with LPS (b, e). Lungs were excised and 
imaged 24 hs after LPS challenge (c, f). Time-course of IL-8-luc activation (B). Results 
are reported as folds of increase (FOI) over baseline. Each point represents the mean ± 
SEM of 6 animals. Statistical analysis was performed by 1way ANOVA followed by 
Dunnett’s multiple comparisons test, * p<0.05 vs. control. 
 
Figure 23. Immune cells recruitment (A) and cytokines expression (B) in WT and CFTR-
KO (CF) mice 24 hours after instillation with P. aeruginosa VR1 10X-concentrated 
culture supernatant. TSB was used as control. The amount of immune cells found in 
BALF was expressed as number of cells per μl (A). Cytokines concentration was 
expressed as pg/ml (B). Three mice were used for every time point and the experiment 
was replicated three times. Values are expressed as mean ± SEM of the three different 
experiments. Statistical analysis was performed by 1way ANOVA followed by Dunnett’s 
multiple comparisons test, * p<0.05 and ** p<0.01 vs control. 
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Inhibition of P. aeruginosa virulence by clarithromycin decreases lung 
inflammation in CF mice  
We extended the investigation about connection between anti-virulence and anti-
inflammatory effects to other molecules, like the macrolide clarithromycin. 
Performing minimum inhibitory concentration (MIC) assay, we established that 
doses up to 128 µg/ml clarithromycin has no bacteriostatic activity against VR1. 
Growth of VR1 in presence of 45 µg/ml (sub-MIC dose) clarithromycin caused a 
significant reduction in the synthesis of pyocyanin, pyoverdine and proteases (Fig. 
24), similar to what previously observed with azithromycin, further supporting 
that macrolides interfere with protein synthesis. By inhibiting the production of P. 
aeruginosa exoproducts, clarithromycin could undermine bacterial virulence and 
indirectly modulate virulence-induced host inflammatory response. 
 
 
Figure 24. Pyocyanin, pyoverdine and proteases concentration was measured in culture 
supernatants from VR1 isolate grown in presence/absence of sub-MIC clarithromycin 
(CLM). Each value represents the mean ± SEM of 3 experiments. Statistical analysis was 
performed by 2-tailed t test, * p<0.05 vs. VR1. 
 
Using the newly-developed CF bIL-8-Luc-transgenic mouse model, we extended 
the investigation to other molecules of interest, like clarithromycin. In both WT 
and KO animals the challenge with VR1 culture supernatant induced after 24 
hours a strong inflammatory response in terms of IL-8 reporter activation (Fig. 25, 
26). The bioluminescence signal lasted longer in KO mice, whose emission after 
48 hours was still significantly higher than in mice challenged with TSB control 
medium (Fig. 25). In both WT and KO animals, the supernatant from VR1+CLM 
provoked only a minor response: the average of photons emitted was significantly 
lower than in mice challenged with VR1 supernatant, and comparable to the 
bioluminescence signal induced by TSB (Fig. 25, 26). These results resemble 
those obtained with azithromycin, supporting that the inhibitory action of 
clarithromycin on P. aeruginosa virulence might decrease the immune response in 
the lungs, with beneficial effects for the animals in terms of reduced 
inflammation, especially in CF-like mice. 
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Figura 25. Representative images (A) and photons measurement (B) of bioluminescence 
emission in KO mice challenged with culture supernatant from VR1 ± 45 µg/ml 
clarithromycin (CLM). Control mice were treated with TSB. Photons emission is 
expressed as folds of increase (FOI) over baseline. Each point represents the mean ± SEM 
of 6 animals. Statistical analysis was performed by 2way ANOVA followed by Dunnett’s 
multiple comparisons test, *p<0.05 and **** p<0.0001. 
 
 
Figure 26. Representative images (A) and photons measurement (B) of bioluminescence 
emission in WT mice challenged with 10X-concentrated culture supernatant from VR1 ± 
45 µg/ml clarithromycin (CLM). Control mice were treated with TSB. Photons emission 
is expressed as folds of increase (FOI) over baseline. Each point represents the mean ± 
SEM of 6 animals. Statistical analysis was performed by 2way ANOVA followed by 
Dunnett’s multiple comparisons test, **** p<0.0001. 
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P. aeruginosa protease inhibition decreases lung inflammation in mice  
We carried on the investigation on the inflammatory role of P. aeruginosa 
proteases testing more molecules chemically similar to Ilomastat, belonging to the 
hydroxamate-based group of metalloprotease inhibitors. We evaluated the effects 
of Marimastat and Batimastat; to our knowledge, the effect of these molecules on 
bacterial proteases has never been studied. Protease activity in VR1 culture 
supernatant was inhibited by Marimastat, but not by its chemical analogue 
Batimastat (Fig. 27). Thus, along with Ilomastat, we continued testing only 
Marimastat in vivo in bIL-8-Luc KO and WT mice. 
 
Figure 27. Protease activity in 1X (A) and 10X-concentrated (B) VR1 culture supernatant 
was measured in presence of increasing concentrations of MMP inhibitors Marimastat 
and Batimastat. Each value represents the mean ± SEM of 3 experiments. Statistical 
analysis was performed by 1way ANOVA followed by Dunnett’s multiple comparisons 
test, * p<0.05, ** p<0.01 and *** p<0.001 vs. non-treated supernatant. 
 
In bIL-8-Luc-transgenic KO mice intratracheally instilled with VR1 culture 
supernatant pre-treated with 50 µM Ilomastat, there was no significant reduction 
of the bioluminescence signal in comparison to animals challenged with non-
pretreated supernatant (Fig. 28), differently to what previously observed in BalbC 
mice. But increasing the dose to 150 µM Ilomastat, a reduced bioluminescence 
was observed. The same concentration of Marimastat was even more effective in 
reducing lung inflammation in KO mice in terms of exogenous IL-8 promoter 
activation; indeed, bioluminescence emission was still significantly reduced at 48 
hours after the intratracheal challenge with VR1 supernatant pre-treated with 
Marimastat, in comparison to non-treated supernatant (Fig. 28). We observed 
comparable results in WT mice challenged with VR1 pre-treated with 150 µM 
Ilomastat or Marimastat (Fig. 29). Thereby, Ilomastat and Marimastat might be 
good candidates for further in vivo studies in models of infection with virulent 
strains expressing high metalloprotease levels. 
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Figure 28. IL-8-mediated bioluminescence emission in C57BL/6J KO mice after 
instillation with 10X-concentrated VR1 culture supernatant untreated or pre-treated with 
50 or 150 µM Ilomastat (ILM) or 150 µM Marimastat (MAM). TSB was used as control. 
Photons emission recorded after 4, 24 and 48 hs is expressed as folds of increase (FOI) 
over baseline. Each value represents the mean ± SEM of 6 animals. Statistical analysis 
was performed by 2way ANOVA followed by Dunnett’s multiple comparisons test, ** 
p<0.01, *** p<0.001 and **** p<0.0001 vs. VR1. 
 
Figure 29. IL-8-mediated bioluminescence emission in C57BL/6J WT mice after 
instillation with 10X-concentrated VR1 culture supernatant untreated or pre-treated with 
150 µM Ilomastat (ILM) or Marimastat (MAM). TSB was used as control. Photons 
emission recorded after 4, 24 and 48 hs is expressed as folds of increase (FOI) over 
baseline. Each value represents the mean ± SEM of 6 animals. Statistical analysis was 
performed by 2way ANOVA followed by Dunnett’s multiple comparisons test, *p<0.05, 
** p<0.01, and *** p<0.001 vs. VR1. 
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6.3. Discussion  
P. aeruginosa is considered the main airway pathogen in cystic fibrosis, affecting 
a high percentage of patients, particularly adults. Especially during early 
colonization, P. aeruginosa releases a multitude of virulence factors which 
contribute to lung damage and trigger airways immune defenses, promoting final 
lung failure [30]. We studied the effects of P. aeruginosa virulence on lung 
inflammation using a transgenic mouse model which allows in vivo 
bioluminescence imaging of an exogenous bovine interleukin-8 promoter 
activation. Although mouse cells do not express a clear homologous IL-8 gene, 
the murine transcriptional apparatus can activate or repress the exogenous 
promoter driving a luciferase reporter gene [302]. The non-invasive nature of this 
mouse model and the possibility for bIL-8-luc-transgenic mice to be stimulated 
for long time enables the monitoring of the inflammatory process longitudinally in 
the same mouse. This represents an obvious advance for functional as well as 
pharmacological studies, reducing the number of sacrificed animals and the costs 
of housing, and increasing the data quality by lowering the inter-animal 
variability, since each mouse represents its own control. IL-8 promoter activation 
by P. aeruginosa virulence factors was verified in vitro, and in vivo in BalbC 
mice. In both systems, the treatment induced a strong, concentration-dependent 
bioluminescence emission, indicating activation of the exogenous bIL-8 promoter. 
In mice, the emission was limited to the lungs area, thereby confirming the correct 
transfection of lung tissue and the effectiveness of intratracheal challenge. 
Furthermore, the model was successfully applied to Cftrtm1Unc knockout (KO) 
mice into C57Bl/6J background, a CF mouse model reported to develop lung 
disease [303]. Moreover, post-bronchiolar hyperinﬂation of alveoli reported in 
this model is consistent with obstructive small airway disease, which is a 
characteristic early feature of the human disease [304]. In bIL-8-Luc-transgenic 
KO mice, intratracheal challenge with P. aeruginosa pro-inflammatory products 
such as LPS and the products released in culture supernatant induced 
bioluminescence emission in the lungs area, immune cells recruitment and 
inflammatory cytokines expression, indicating a local inflammatory response. 
Although IL-8 activation in KO mice resulted in a stronger and longer-lasting 
bioluminescence signal as compared to WT animals, the other lung inflammatory 
markers such as immune cells, cytokines and histology did not show significant 
differences between the two mouse strains at 24 hours after the challenge. Though 
surprising at a first glance, a differential degree of strain sensitivity to pro-
inflammatory stimuli has been reported [323]. Indeed, the same stimulus in BalbC 
mice induced a higher number of recruited inflammatory cells than in the C57Bl/6 
mouse strain, supporting this interpretation. Moreover, the reporter gene relies on 
bIL-8 promoter, which responds mainly to NF-κB while additional master genes, 
like AP-1 (Fos/Jun), NFATs, and STATs, control the expression of several 
cytokines [324]. Such additional pathways might bypass the need of full NF-κB 
recruitment, and can be activated in different mouse strains. In this specific case, 
the differential response to agonists further highlight the critical role of CF 
background in controlling inflammatory response, and support the notion that 
differential responses in CFTR-defective mice may occur, in line with the pro-
inflammatory phenotypes recognized in humans. 
53 
 
 
Patients with chronic P. aeruginosa lung infection are often treated with 
azithromycin, a macrolide antibiotic known to interact with the 50S ribosomal 
subunit and affect specific genes and transcriptional factors involved in the 
regulation of virulence [202]. Azithromycin has no bactericidal activity against P. 
aeruginosa, but could inhibit the synthesis of secreted virulence factors such as 
pyocyanin, pyoverdine and proteases. Particularly, we observed that 
metalloprotease activity and alkaline protease expression were inhibited in both 
culture supernatant and bacterial lysate, confirming the macrolide inhibitory effect 
on metalloprotease synthesis. The observed anti-virulence activity is likely to be 
involved in the clinical benefits associated with azithromycin treatment. 
Supernatant collected after growth in presence of azithromycin induced lower 
bioluminescence emission, immune cells recruitment and cytokines expression in 
bIL-8-Luc BalbC mice in comparison to supernatant from non-treated bacteria. A 
similarly low pro-inflammatory effect was shown by the supernatant from a 
lowly-virulent P. aeruginosa isolate. These data support the involvement of 
bacterial virulence down-regulation in the beneficial effects of azithromycin in the 
first year of therapy, while the reduced efﬁcacy associated with longer treatment 
duration might be due to development of bacterial resistance to azithromycin anti-
virulence activity. Thereby, evaluation of molecules with similar antibacterial 
mechanisms is important to find alternative treatments for patients not responding 
to azithromycin or for whom the treatment lost efficacy [208, 325]. A candidate 
might be macrolide clarithromycin, which showed clinical effectiveness in 
treating DPB and has been studied as therapy for other respiratory diseases [231-
236]. Clarithromycin effects in CF patients were also evaluated in different 
studies, although with contrasting outcomes [237-240]. Like azithromycin, 
clarithromycin has no bactericidal activity against P. aeruginosa, but could down-
regulate synthesis of P. aeruginosa virulence factors [217, 241]. In bIL-8-Luc KO 
and WT Cftrtm1Unc mice, supernatant collected after growth in presence of 
clarithromycin induced lower bioluminescence emission in comparison to 
supernatant from non-treated bacteria. From these results, we conclude that 
clarithromycin acts similarly to azithromycin on P. aeruginosa by reducing the 
synthesis of various exoproducts involved in bacterial virulence and the associated 
host inflammatory response. The inhibitory action of clarithromycin on P. 
aeruginosa virulence seems to decrease the immune response in the lungs, with 
beneficial effects for the animals in terms of reduced inflammation, especially in 
KO mice. Our results support the possible efficacy of clarithromycin for treating 
CF patients and encourage more clinical trials to assess the effectiveness of this 
therapy, which gain particular interest when considering the possibility of aerosol 
administration; indeed, its formulation as dry powder inhaler is currently under 
investigation [250, 251]. Thus, local administration in the airways might represent 
an option for the treatment of chronic P. aeruginosa-infected patients, especially 
for those not responding to other therapies. To our knowledge, clarithromycin 
treatment has never been tested in patients that already showed no improvement 
under azithromycin therapy. A clinical study in this group of patients might 
clarify the possible use of clarithromycin as an alternative therapy, and help to 
understand the involvement of P. aeruginosa resistance in azithromycin long-
treatment ineffectiveness. 
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Among many factors, proteases from both host and bacteria play a critical role in 
CF lung disease, contributing to lung tissue damage and exacerbation of host 
inflammatory response. P. aeruginosa exogenous proteases such as AprA and 
LasB can alter mucociliary clearance, degrade lung tissue and dysregulate host 
immune system, thus strongly contributing to lung disease [156]. We showed that 
downregulation of protease production is part of the anti-virulence effects of 
macrolides azithromycin and clarithromycin, and it might be involved in their 
anti-inflammatory effect associated with virulence inhibition. Thus, molecules 
targeting proteases might represent an alternative anti-inflammatory therapy. 
Broad spectrum hydroxamates are attractive candidates, since many members 
entered clinical trials as cancer therapeutics, although with disappointing results 
as regards their effectiveness in delaying disease progression [263, 264]. 
Hydroxamate-based broad spectrum human matrix metalloprotease inhibitor 
Ilomastat had previously been reported to inhibit P. aeruginosa elastase [255]; 
indeed, treatment of P. aeruginosa culture supernatant resulted in a strong 
reduction of protease activity. We also tested proteases inhibition by two more of 
these molecules, Batimastat and Marimastat: only the latter could decrease 
bacterial protease activity. In order to evaluate P. aeruginosa secreted proteases as 
possible targets of anti-inflammatory therapy, we tested in vivo the effect of their 
inhibition on lung inflammation. In bIL-8-Luc-transgenic BalbC mice challenged 
with Ilomastat-pretreated supernatant, we observed a strong reduction of 
bioluminescence and immune cells recruitment in comparison to non-pretreated 
supernatant. Differently, in KO Cftrtm1Unc mice the same Ilomastat concentration 
was not able to down-regulate the inflammatory response, probably due to a 
differential degree of strain sensitivity to the pro-inflammatory stimuli [323], but 
we found that a higher dose could reduce IL-8 promoter activation in both WT 
and KO mice. Similar to Ilomastat, inactivation of P. aeruginosa secreted 
proteases by Marimastat showed a beneficial effect on lung inflammation in bIL-
8-Luc-transgenic WT and KO mice in terms of lower bioluminescence emission 
in comparison to non-pretreated supernatant, thereby reducing lung inflammatory 
response. These results highlight the key role played by P. aeruginosa proteases 
in host inflammatory response, since the inhibition of the sole bacterial proteases 
determined a significantly milder lung inflammation. Thus, anti-protease 
strategies to dampen the inflammatory response and concomitant airways damage 
might be an interesting additional therapy for CF lung disease. We tested two 
candidate molecules with interesting characteristics: while Marimastat is orally 
available, Ilomastat is under evaluation as inhaled therapy [262], which would 
allow local airways treatment. Furthermore, anti-protease therapy might avoid the 
limitations due to resistance development, a typical feature of antibiotic 
treatments [252]. 
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7. PROJECT 2 - ADAPTIVE MICROBIAL INTERACTIONS BETWEEN PSEUDOMONAS 
AERUGINOSA AND ACHROMOBACTER XYLOSOXIDANS 
In the present study, we observed the evolution of P. aeruginosa and A. 
xylosoxidans strains during chronic co-infection of CF lungs, and evaluated 
possible inter-species interactions that might have been engaged during this time, 
while the two microorganisms were neighbors sharing the same environment. 
Although the occurrence of close microbial interactions within the CF lung is not 
yet clear, our study might help to understand the role of bacterial interactions on 
survival and persistence in the human host.  
 
7.1. Materials & Methods 
Bacterial strains 
P. aeruginosa and A. xylosoxidans clinical strains were longitudinally collected 
from sputum samples of a chronically co-infected patient followed at 
Rigshospitalet, Copenhagen, Denmark (kind gift of Dr. Helle Krogh Johansen). 
Isolates were collected in 2005 and 2008, and stored in 20% glycerol at -80°C.  
Colony morphology 
Bacterial strains were plated on LB agar and incubated at 37°C for 24-48 hours. 
Single colonies were observed and photographed. Different features were 
observed and reported: size, shape, color, edge, and mucoidy. 
Growth curves 
Bacterial strains were plated on LB agar and incubated at 37°C for 24-48 hours. 1-
2 colonies were inoculated in 10 ml LB medium shaking at 37°C overnight. OD600 
was measured using a spectrophotometer, cultures were diluted to 0.05 OD/ml in 
LB medium and 150 µl/well were incubated in a 96-well plate for 20-24 hours 
shaking at 37°C. Using an automated plate reader, A600 was measured every 20 
minutes. Growth rate was calculated using GraphPad Prism software. 
Culture supernatant collection 
A. xylosoxidans strains were plated on LB agar and incubated at 37°C for 24-48 
hours. 1-2 colonies were inoculated in 10 ml LB medium shaking at 37°C for 16 
hours. OD600 was measured and cultures were diluted to 0.1 OD/ml in 10 ml of 
LB medium. After shaking at 37°C for 16 hours, cultures were diluted to 1 OD/ml 
and centrifuged at 7000 g for 30 min at 4°C. Supernatants were collected and 
sterile-filtered. 
Adhesion assay 
Bacterial strains were plated on LB agar and incubated at 37°C for 24-48 hours. 1-
2 colonies were inoculated in 10 ml LB medium shaking at 37°C overnight. OD600 
was measured using a spectrophotometer, cultures were diluted to 0.05 OD/ml in 
LB medium and 150 µl/well were incubated in a 96-well plate for 20-24 hours at 
37°C. After measuring A600, wells were washed twice with water to remove 
unattached cells, and surface-attached cells were stained with 0.1% crystal violet 
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solution for 15 minutes. Wells were rinsed and washed 3 times with water, then 
dried for 1-2 hours. 30% acetic acid was added, incubated at room temperature for 
15 minutes, and A590 was measured. 30% acetic acid was used as blank. In 
competition assays, P. aeruginosa adhesion was measured in presence/absence of 
10% A. xylosoxidans culture supernatant. 
Protease assay 
Protease activity in culture supernatants was determined by azocasein assay. 
Briefly, 350 µl reaction mixture containing 0.1 M Tris-HCl, pH 8.0, and 1% 
azocasein (Sigma-Aldrich, previously resuspended in 0.5% NaHCO3) was added 
to 150 µl supernatant and incubated at 37°C for 20 minutes shaking. After 
addition of 1 ml 7% ice-cold perchloric acid, the solution was centrifuged. 150 µl 
of 10 N sodium hydroxide were added to the clear supernatant and OD430 was 
measured. One protease unit was calculated as the amount of enzyme producing 
an increase of 0.1 OD per hour. 
Pulse field gel electrophoresis 
Bacterial suspensions were prepared from individual bacterial colonies directly 
obtained from cultures incubated overnight on Blood Columbia agar plates. The 
suspensions were adjusted to a concentration of 109 CFU/ml, in EDTA-saline 
buffer (75 mmol/L NaCl and 25 mmol/L EDTA, pH 7.5). The cell suspension was 
mixed with an equal volume of 1% low-melting point agarose and was allowed to 
solidify in a 100 μL plug mould. The agarose plug was incubated for 24 h at 37 °C 
in 500 μL of lysis buffer (6 mmol/L Tris–HCl (pH 7.6), 0.1 mol/L EDTA, 1 mol/L 
NaCl, 0.5% Brij®58 (polyoxyethylene (20) cetyl ether; Sigma), 0.4% sodium 
deoxycholate, 0.5% sodium lauryl sarcosine and 1 mg/mL lysozyme). The lysis 
buffer was replaced with 500 μL of proteinase K buffer (1% sodium lauryl 
sarcosine, 0.5 mol/L EDTA (pH 9) and proteinase K (50 μg/mL; Sigma)) and this 
solution was incubated with gentle shaking at 50 °C for 20 h. The plugs were then 
washed four times for 30 min at 37 °C with 10 mL of Tris–EDTA buffer (10 
mmol/L Tris–HCl (pH 8) and 1 mmol/L EDTA). One-third of a slice of each plug 
was cut and incubated for 18-20 h with 30 U of SpeI (Bio-Rad Laboratories) in 
the restriction buffer (Promega Buffer). DNA restriction fragments were separated 
in a PFGE apparatus at 14 °C, 6 V/cm, for 20 hours with a time switch of 2-40 s. 
The gel was stained with gel-red and visualized with a UV system. According to 
the criteria by Tenover et al., isolates were considered to be genetically 
indistinguishable or identical if the restriction fragments differed in no more than 
3 bands and the corresponding bands had identical apparent size [306].  
GFP reporter construct 
P. aeruginosa strains were tagged with a mini-Tn7 construct carrying gentamycin 
resistance and green fluorescent protein GFPmut3b gene under the control of the 
growth-dependent E. coli ribosomal promoter rrnB P1 (kind gift of Prof. Søren 
Molin, Technical University of Denmark). The construct can be introduced in P. 
aeruginosa by conjugative transfer. 
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Bacterial conjugation 
Recipient P. aeruginosa strains were grown overnight in 10 ml LB medium at 
42°C shaking. E. coli donor strain and E. coli helper strains pRK2013 and pNTS2 
were grown overnight at 30°C shaking in 10 ml LB medium added with 100 
µg/ml gentamycin, 100 µg/ml ampicillin or 25 µg/ml kanamycin, respectively. 
Bacterial cultures were centrifuged at 7.000 rpm for 10 minutes and pellet was 
resuspended in 10 ml LB medium. 3 ml recipient were mixed with 1 ml of each 
E.coli strain. A 200 µl drop was put in the center of a LB agar plate, dried for 1-2 
hours and incubated at 37°C overnight. Bacteria were retrieved with a sterile loop, 
resuspended in LB medium and plated on LB agar containing gentamycin and 
trimethoprim, to select for transconjugants. Single colonies were checked for 
fluorescence emission and mini-Tn7 insertion, streaked on LB agar and stored in 
20% glycerol at -80°C.  
Colony PCR verification of mini-Tn7 insertion 
Single transconjugant colonies were picked and mixed with the following 
reagents: 2.5 µl DMSO, 1 µl 10 mM dNTPs, 5 µl 10x Taq buffer (containing 
MgCl2), 1 µl 30 pmol/ µl PTn7R primer, 1 µl  30 pmol/ µl PglmS Fw primer, 0.5 
µl 5 U/ µl Taq polymerase, and water up to 50 µl. PTn7R and PglmSF primers 
sequences are reported by Choi and Schweizer. PCR was performed as follows: 
95 °C for 5 min; 95 °C for 45 s, 59 °C for 30 s, 72 °C for 20 s, repeat for 30 
cycles; 72 °C for 10 min. An aliquot of the PCR reaction was analyzed by gel 
electrophoresis on 2% agarose gel in TAE buffer (run at a constant 100 V for 1 h). 
A single PCR fragment of approximately 272 bp should be observed. 
Fluorescence production curves 
P. aeruginosa GFP-tagged strains and A. xylosoxidans strains were plated on LB 
agar and incubated at 37°C for 24-48 hours. 1-2 colonies were inoculated in 10 ml 
LB medium shaking at 37°C overnight. OD600 was measured using a 
spectrophotometer, cultures were diluted to 0.05 OD/ml in LB medium and 150 
µl/well were incubated in a 96-well plate for 20-24 hours shaking at 37°C. For 
competition experiments, 75 µl/well of P. aeruginosa and A. xylosoxidans were 
mixed. Using an automated plate reader, fluorescence (excitation 475 nm, 
emission 520 nm) and A600 were measured every 20 minutes. Fluorescence rate 
was calculated using GraphPad Prism software. 
Flow-chamber biofilm 
Flow-chamber system was assembled and sterilized following the protocol from 
M. W. Nielsen and colleagues. Bacterial strains were plated on LB agar and 
incubated at 37°C for 24-48 hours. 1-2 colonies were inoculated in 10 ml LB 
medium shaking at 37°C overnight. OD600 was measured using a 
spectrophotometer, cultures were diluted to 0.05 OD/ml in saline solution. 250 µl 
of bacterial culture were injected in each flow-cell channel. Flow cells were left 
upside-down for an hour without flow, to let bacteria attach on the cover glass. 
Flow cells were turned and the system was incubated at 30°C up to 5 days with 
flow. Biofilms were grown in A10 minimal medium added with MgCl2, CaCl2 
and trace metals. 
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Confocal microscopy 
Biofilm formation was observed every day by confocal laser scanning microscopy 
of GFP-tagged P. aeruginosa strains and Syto62 staining of total cells. For 
statistical analysis, at least 7 pictures/channel were taken, homogeneously 
distributed along the channel. Pictures were visualized and elaborated using 
Imaris 7.4 software. Biomass was calculated using Comstat software. 
Statistical analysis 
Statistical analysis was performed using GraphPad Prism software. Growth rates, 
fluorescence rates, adhesion and protease activity were analyzed by unpaired t 
test. Biofilm biomass was analyzed by Mann-Whitney test for non-parametric 
data. 
 
7.2. Results 
Phenotypic and genotypic characterization of longitudinal isolates  
P. aeruginosa and A. xylosoxidans strains were longitudinally collected from a 
chronically co-infected CF patient twice, in 2005 and 2008. Pulse field gel 
electrophoresis profiles (PFGE) of longitudinal isolates showed high similarity: P. 
aeruginosa profiles were identical, while A. xylosoxidans profiles differed in 2 
bands (Fig. 30). According to the criteria by Tenover and collegues [306], the 
longitudinal isolates can be considered genetically indistinguishable. Thus, PFGE 
analysis confirmed that the patient was colonized with the same P. aeruginosa 
and A. xylosoxidans genotypes for 3 years. 
 
Figure 30. Representative image of PFGE profiles of P. aeruginosa (PA) and A. 
xylosoxidans (AX) longitudinal isolates collected in 2005 and 2008. 
 
During the 3 years long co-infection, P. aeruginosa underwent phenotypic 
evolution known to occur during chronic infection. Colony morphology showed a 
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switch towards the mucoid phenotype, characterized by the overproduction of 
alginate, typical of late infection isolates (Fig. 31A). The morphology of the first 
isolate was already different from the typical environmental P. aeruginosa strains, 
usually forming green, swarming colonies, indicating that probably a partial 
evolution might have happened before 2005. Other phenotypic features observed 
were growth and adhesion. Growth rate diminished over time, while adhesion on 
plastic surfaces increased (Fig. 32). Both changes were expected and confirm 
evolution towards a typical CF P. aeruginosa late infection isolate. On the 
contrary, A. xylosoxidans does not show major changes in any of the observed 
features: colony morphology was similar between longitudinal isolates, while 
growth rate and adhesion capability did not present significant differences (Fig. 
31B, 32). Particularly, A. xylosoxidans isolates showed very low adhesion ability 
on plastic surfaces (Fig. 32B). 
 
Figure 31. Representative images of P. aeruginosa (A) and A. xylosoxidans (B) 
longitudinal isolates colony morphology. Single colonies were photographed after growth 
for 24-48 hours at 37°C on LB agar.  
 
 
Figure 32. Growth rate (A) and adhesion (B) ability of P. aeruginosa and A. xylosoxidans 
isolates. Lab strains P. aeruginosa PAO1 and A. xylosoxidans CIP71.32 were used as 
controls. Growth rate was calculated from 24 hours growth curves in LB medium. Each 
value represents the mean ± SD of 3 experiments. Statistical analysis was performed by t 
test, *** p<0.001 (A). Adhesion was measured by crystal violet staining of surface-
attached bacteria divided by A600 of non-attached bacteria. Each value represents the 
mean ± SEM of 3 experiments. Statistical analysis was performed by t test, * p<0.05 (B). 
A. xylosoxidans initially interferes with P. aeruginosa growth  
To observe possible synergistic/competitive interactions between the co-isolated 
P. aeruginosa and A. xylosoxidans strains, mixed planktonic cultures were grown. 
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P. aeruginosa isolates were previously tagged with a construct containing GFP 
gene under the control of a growth-dependent promoter, thus fluorescence 
emission increases during bacterial growth, as shown in figure 33A. The 
fluorescence rate was then used as a read-out of bacterial growth rate.  
P. aeruginosa fluorescence emission was measured during growth in 
presence/absence of A. xylosoxidans: a lower fluorescence rate was observed 
when the first P. aeruginosa isolate was cultured in the presence of the first A. 
xylosoxidans isolate. On the contrary, this inhibitory effect was not observed 
when the late isolates were co-cultured (Fig. 33B).  
 
Figure 33. Effects of A. xylosoxidans on P. aeruginosa growth-dependent fluorescence 
rate. Fluorescence emission curves of GFP-tagged P. aeruginosa isolates (A). 
Fluorescence rate of GFP-tagged P. aeruginosa strains cultured in presence/absence of 
the co-isolated A. xylosoxidans strain. Fluorescence rate was calculated from 24 hours 
fluorescence emission curves in LB medium. Each value represents the mean ± SEM of 3 
experiments. Statistical analysis was performed by t test, * p<0.001. 
A. xylosoxidans initially interferes with P. aeruginosa biofilm formation  
Mono-species and multi-species biofilms were grown in flow-chamber system up 
to 5 days. As shown in figure 34A, P. aeruginosa isolates could form big, stable 
aggregates firmly attached on the glass surface. On the contrary, A. xylosoxidans 
strains confirmed their poor adhesion ability on abiotic surfaces like plastic and 
glass, forming sporadic, unstable, small aggregates characterized by scattering and 
dispersal of planktonic cells (Fig. 34B).  
 
Figure 34. Representative images of P. aeruginosa (A) and A. xylosoxidans (B) biofilm 
structures. Biofilms were grown in flow-chambers system for 5 days and monitored by 
confocal microscopy. P. aeruginosa strains were previously tagged with GFP (green), A. 
xylosoxidans was stained with Syto62 (red). 
61 
 
 
Interestingly, when cultured together the two microbes could form mixed 
biofilms, suggesting that A. xylosoxidans adhesion is probably enhanced on biotic 
surfaces. In mixed biofilms, we observed a difference between the two stages of 
infection: in the early stage, A. xylosoxidans interferes with P. aeruginosa biofilm 
formation. As shown in figure 35, P. aeruginosa aggregates are smaller in 
presence of A. xylosoxidans; this observation is confirmed by the quantification of 
P. aeruginosa biomass, which is reduced in mixed biofilms (Fig. 35C). As 
previously observed for P. aeruginosa growth, the inhibitory effect of A. 
xylosoxidans on P. aeruginosa biofilm formation is visible only at the beginning 
of co-infection, while 3 years later the two species can form mixed aggregates 
without any visible interference (Fig. 36A-B). P. aeruginosa biomass 
quantification confirmed this observation (Fig. 36C). 
 
Figure 35. Representative biofilm images of the first P. aeruginosa strain in absence 
(A)/presence (B) of the co-isolated A. xylosoxidans. Biofilms were grown in flow-
chambers system for 5 days and monitored by confocal microscopy. P. aeruginosa strains 
were previously tagged with GFP (green), A. xylosoxidans was counterstained with 
Syto62 (red). P. aeruginosa biomass was calculated using Comstat2 software. Each value 
represents the mean ± SEM of 3 experiments. Statistical analysis was performed by 
Mann-Whitney test for non-parametric data, * p<0.05 (C). 
 
 
Figure 36. Representative biofilm images of the second P. aeruginosa strain in absence 
(A)/presence (B) of the co-isolated A. xylosoxidans. Biofilms were grown in flow-
chambers system for 5 days and monitored by confocal microscopy. P. aeruginosa strains 
were previously tagged with GFP (green), A. xylosoxidans was counterstained with 
Syto62 (red). P. aeruginosa biomass was calculated using Comstat2 software. Each value 
represents the mean ± SEM of 3 experiments (C).  
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A. xylosoxidans exoproducts initially interfere with P. aeruginosa adhesion 
P. aeruginosa early isolate showed a significantly lower adhesion ability when 
grown in presence of the co-isolated A. xylosoxidans culture supernatant, 
containing all the exoproducts released during bacterial growth, including possible 
virulence factors; again, this effect was not observed between the late isolates, 
suggesting a competitive effect in the initial stages of co-infection, probably due 
to virulence factors secreted by A. xylosoxidans (Fig. 37).  
 
 
Figura 37. P. aeruginosa adhesion in absence (untreated) or presence of the co-isolated 
A. xylosoxidans culture supernatant (SN). Adhesion was measured by crystal violet 
staining of surface-attached bacteria divided by A600 of non-attached bacteria. Each value 
represents the mean ± SEM of 3 experiments. Statistical analysis was performed by t test, 
* p<0.05. 
 
A. xylosoxidans down-regulates protease secretion over time 
To identify possible factors involved in the initial inhibitory effect of A. 
xylosoxidans against P. aeruginosa, we searched for the presence of secreted 
virulence factors in A. xylosoxidans culture supernatant. We measured secreted 
proteases, which are virulence factors typical of many bacterial species and one of 
the few reported in A. xylosoxidans strains. We detected high protease activity in 
the culture supernatant of the early isolate, while the activity was significantly 
lower in the late strain (Fig. 38). This finding might help to explain the inhibitory 
effects observed only at the beginning of the co-infection. 
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Figure 38. Protease activity in A. xylosoxidans culture supernatant measured by 
azocasein assay. Protease activity is expressed as U/ml. Each value represents the mean ± 
SEM of 3 experiments. Statistical analysis was performed by t test, ** p<0.01. 
 
P. aeruginosa develops resistance against A. xylosoxidans exoproducts 
To verify weather A. xylosoxidans virulence down-regulation is the only 
responsible for the apparent reciprocal adaptation of the two microbes, we 
evaluated the effect of virulence factors secreted by the first A. xylosoxidans 
isolate also against the second P. aeruginosa isolate: this late strain did not show a 
lower adhesion ability when grown in presence of the early A. xylosoxidans 
culture supernatant, containing proteases (Fig. 39). This observation suggests that 
the adaptation of P. aeruginosa in CF airways helps the bacterium to withstand A. 
xylosoxidans virulence. 
 
Figura 39. P. aeruginosa adhesion in absence (untreated) or presence of culture 
supernatant (SN) from the first A. xylosoxidans isolate. Adhesion was measured by 
crystal violet staining of surface-attached bacteria divided by A600 of non-attached 
bacteria. Each value represents the mean ± SEM of 3 experiments.  
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7.3. Discussion  
For long time CF lung infection has been studied and treated as a disease caused 
by a single pathogen, while nowadays we are aware of its polymicrobial nature. 
Both pathogens and commensals are isolated from CF airways, leading to 
consider the whole microbial community as participant in the disease [88, 89]. 
Within communities, intra- and inter-species interactions can take place and 
potentially influence the course of the infection [90, 91]. P. aeruginosa 
interactions with other well-known CF pathogens such as Burkholderia spp. and 
S. aureus have extensively been studied [125-134]. On the contrary, P. 
aeruginosa interactions with emerging pathogens such as S. maltophilia and A. 
xylosoxidans have not been clearly evaluated yet, probably because the clinical 
relevance of these microorganisms became evident only recently. In the present 
investigation, we focused on A. xylosoxidans, which lately gained attention as an 
important pathogen that can cause chronic lung infection, further complicated by 
its innate and acquired multidrug resistance [308]. Despite the increasing number 
of patients becoming chronically infected with this microorganism, and the 
frequent co-isolation of A. xylosoxidans and P. aeruginosa from the same sputum 
samples, studies about their possible interactions still lack. We investigated the 
behavior and evolution of P. aeruginosa and A. xylosoxidans clinical isolates 
sharing the same CF airway environment for three years. 
P. aeruginosa is known to evolve at both genotypic and phenotypic level during 
chronic infection of CF airways. Particularly, the appearance of mucoid 
morphology is the most typical feature of late chronic isolates, due to mutations in 
mucA gene leading to overproduction of alginate [101]. This evolution was 
evident from the first non-mucoid strain isolated in 2005 to the second mucoid 
strain collected in 2008. We also observed reduction in the growth rate over time, 
probably due to down-regulation of central metabolism usually associated with 
mucA mutations [115], as well as increase in adhesion ability. Adhesion is another 
typical feature of chronic P. aeruginosa, allowing the bacteria to grow in biofilm 
communities. Indeed, both P. aeruginosa isolates could form large and stable 
aggregates. On the contrary, A. xylosoxidans did not show any of these phenotypic 
changes. Both isolates grew slowly, showed poor adhesion and could form only 
sporadic, loosely-attached biofilm structures characterized by dispersal of 
planktonic cells. This difference in adaptation between the two microorganisms 
suggests that A. xylosoxidans survival and successful lung colonization relies on 
different mechanisms than P. aeruginosa. Thus, further studies about this 
bacterium might unveil new features involved in microbial persistence within CF 
airways. 
As regards the interaction between the two pathogens, in the early stage of co-
infection A. xylosoxidans showed inhibitory effects against P. aeruginosa, 
indicating an initial competition. This inhibitory activity was observed at various 
levels, interfering with P. aeruginosa growth, adhesion and biofilm formation. 
Interestingly, the nature of this interplay changed with time: in the late stage of 
co-infection the inhibitory effects disappeared, in favor of a more indolent 
cohabitation or even cooperation, which might represent a survival advantage. In 
the late stage, the two microbes could also grow together in mixed biofilm 
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communities, supporting that close microbial interactions might occur between 
them. Indeed, bacterial proximity within biofilm communities can favor social 
exchanges of signal molecules and genetic elements, influencing many aspects of 
the community itself, like microbial composition, nutrients availability, and 
antibiotic resistance [92, 93]. Although the occurrence of close microbial 
interactions within the CF airway has not been demonstrated yet, in this particular 
case their relevance should be considered: A. xylosoxidans is rich in mobile 
genetic elements carrying antibiotic resistance [313], whose exchange and 
acquisition by other microbes like P. aeruginosa might influence the course of 
infection and the outcome of antibiotic therapies. 
Trying to elucidate the mechanisms underlying the initial competition observed 
between A. xylosoxidans and P. aeruginosa, we evaluated proteases secretion by 
A. xylosoxidans. Proteases are common bacterial virulence factors involved in 
infectivity and directed against both host and other microorganisms. The early A. 
xylosoxidans isolate showed strong protease secretion. Although genes related to 
protease regulation were previously found in A. xylosoxidans genome [316], to 
our knowledge the actual presence of extracellular proteases had never been 
reported yet. Interestingly, proteases secretion decreased in the late stage of 
infection. This is the first adaptive change that we could observe between the two 
A. xylosoxidans isolates, suggesting virulence modulation as a mechanism 
involved in long-term colonization of CF airways by this pathogen. Along with 
protease down-regulation in A. xylosoxidans, we observed an increase of P. 
aeruginosa resistance to these virulence factors, probably resulting from 
adaptation towards the mucoid phenotype. Thereby, the evolution from initial 
competition to co-habitation observed between the two pathogens probably 
depends on adaptive changes involving both microbes and represents a survival 
advantage in CF airways.  
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8. Conclusions 
Understanding which mechanisms are primarily involved in successful 
colonization of CF lungs by P. aeruginosa and other pathogens is essential to find 
new therapeutic approaches and develop appropriate treatment regimens. In this 
thesis, two studies were described, that contributed to this knowledge and pointed 
at bacterial virulence and microbial interactions as critical players.  
We demonstrated that P. aeruginosa virulence is strongly involved in host 
inflammatory response by monitoring in vivo the activation of an exogenous IL-8 
promoter. Although this method does not permit to study the molecular and 
cellular mechanisms underlying immune activation, it gives an appropriate read-
out of the inflammatory CF response and is suitable for the evaluation of 
treatments to dampen lung inflammation. We identified macrolides and protease 
inhibitors as candidates for anti-inflammatory therapy, thanks to their anti-
virulence action on P. aeruginosa. As for clarithromycin, we encourage more 
clinical trials to assess the effectiveness of this therapy, while further in vivo 
studies about protease inhibitors are needed to better understand the specificity of 
their action and find appropriate formulations and doses in view of a possible 
clinical usage. 
We added new insights to the mechanisms underlying the colonization of CF 
airways by the pathogen A. xylosoxidans and to its interplay with P. aeruginosa. 
We reported the secretion of proteases by A. xylosoxidans, and identified protease 
down-regulation as an adaptive mechanism of this bacterium in the lung 
environment. Although further studies to characterize more A. xylosoxidans 
virulence factors are needed, we speculate that virulence down-regulation might 
have a key role in long-term colonization. As regards its interaction with P. 
aeruginosa, we observed an initial competition evolving towards co-habitation in 
mixed biofilm communities, suggesting that close social interactions and genetic 
exchanges might happen. Further studies are needed to clarify the occurrence of 
these inter-species events and their impact on lung disease. 
 
These studies lead to the following scientific contributions: 
• Stellari F., Bergamini G., Sandri A., Donofrio G., Sorio C., Ruscitti F., 
Villetti G., Asseal B.M., Melotti P., Lleò M.M. In vivo imaging of the lung 
inflammatory response to Pseudomonas aeruginosa and its modulation by 
azithromycin. Journal of Translational Medicine. 2015, 13:251.  
• Stellari F.*, Bergamini G.*, Ruscitti F., Sandri A., Ravanetti F., Donofrio 
G., Boschi F., Villetti G., Sorio C., Assael B.M., Melotti P., Lleò M.M. In 
vivo monitoring of lung inflammation in CFTR-deficient mice. Journal of 
Translational Medicine. 2016, 14:226.  
• Bergamini G.*, Stellari F.*, Sandri A.*, Lleò M.M., Donofrio G., Ruscitti 
F., Boschi F., Sbarbati A., Villetti G., Melotti P., Sorio C. IL-8 transiently 
transgenized mouse model for the in vivo long-term monitoring of the 
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inflammatory response. Journal of Visualized Experiments. 2017 (in-
press), e55499, doi:10.3791/55499. *equal contribution 
• Sandri A., Haagensen J.A.J., Jimenez Fernandez A., Molin S., Krogh 
Johansen H., Lleò M.M. Adaptive microbial interactions between 
Pseudomonas aeruginosa and Achromobacter xylosoxidans [abstract]. In: 
14th ECFS Basic Science Conference; 2017 Mar 29-Apr 1; Albufeira, 
Portugal. Journal of Cystic Fibrosis, in-press. Abstract n. 68. 
• Sandri A., Stellari F., Boschi F., Ortombina A., Bergamini G.*, Lleò 
M.M.*. Matrix metalloprotease inhibitors as anti-inflammatory therapy in 
Pseudomonas aeruginosa lung infection [abstract]. In: 14th ECFS Basic 
Science Conference; 2017 Mar 29-Apr 1; Albufeira, Portugal. Journal of 
Cystic Fibrosis, in-press. Abstract n. 69.  
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